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Abstract 
 
Nef is an HIV -1 accessory protein with a fundamental role for virus replication in vivo and for the 
development of AIDS. Among its several activities, Nef is essential for full HIV-1 infectivity, a function highly 
prominent in lymphoid cells. So far, the mechanism by which Nef promotes HIV-1 infectivity has remained 
elusive. Over the course of 3 years, my PhD research activity has led to the identification of the host 
transmembrane protein SERINC5, and to a lesser extent SERINC3, as potent inhibitors of HIV-1 infectivity 
counteracted by the viral protein Nef [Rosa et al., 2015].  
SERINC5 is predominantly localized on the plasma membrane where it is efficiently incorporated into budding 
HIV-1 virions and impairs subsequent virion penetration of susceptible target cells. Nef relocalizes SERINC5 
to an endosomal compartment preventing its incorporation into HIV-1 particles.  
The ability to counteract SERINC5 is conserved in Nef proteins encoded by different primate 
immunodeficiency viruses, as well as in the structurally unrelated glycosylated Gag from murine leukaemia 
virus (MLV). These examples of functional conservation and convergent evolution emphasize the 
fundamental importance of SERINC5 in the interaction of the host with retroviral pathogens. 
Remarkably, SERINC5 potently inhibits HIV-1 even in the presence of Nef in a dose-dependent manner, 
suggesting that this cellular factor might be exploited as an anti-HIV-1 therapeutic gene. 
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1.1  The importance of studying Retroviruses 
 
The term “Retroviruses” defines a large family of enveloped viruses with single-stranded positive-sense RNA 
genomes. [Coffin et al., 1997]. This virus family owes its name to the reverse transcriptase enzyme discovered 
in 1970 by D. Baltimore and H. M. Temin, who independently showed that retroviral RNA genomes are copied 
into DNA [Baltimore, 1970; Temin and Mizutani, 1970]. Turning over the dogmatic direction of genetic 
information [Crick, 1970], the discovery of reverse transcriptase impacted different fields of biology and 
caused an explosion of attention on research into Retroviruses. The importance of Temin and Baltimore’s 
work led them to receive the Nobel Prize for Physiology and Medicine in 1975. 
Retroviruses infect a wide range of vertebrates ranging from fish to humans [Robertson, 2012]. Being human 
and animal pathogens, Retroviruses therefore arose the research interest from biomedical, agricultural and 
economic point of view. They are in fact responsible for a wide range of human and veterinary diseases 
including different kinds of cancer, immunological disorders and neurological conditions [Coffin et al, 1997]. 
As obligatory intracellular parasites, Retroviruses co-opt host molecular pathways to achieve a proper 
replication. Retroviral infection is the result of a constant compromise between supportive and inhibitory 
factors in the target cells. Supportive factors positively regulate retroviral replication, while on the other hand 
host restriction factors play an inhibitory role targeting different steps of replication. Due to their unique 
replication strategy and intricate life cycle, a better understanding of the molecular mechanisms behind 
host–pathogen interactions can provide novel insights into host cell biology. A more detailed description 
about viral and host factors relationship will be provided later in this dissertation. 
The fast evolution rate of retroviruses [Combe and Sanjuán, 2014; Sanjuán et al, 2010] together with the 
physical and phylogenetic proximity between their different hosts make events of cross-species infection not 
unlikely [Hayward et al, 2013; Parrish et al, 2008]. Epidemics are indeed the outcome of viral adaptation into 
new species. Remarkably, the transfer of an animal pathogen to a human host is a process defined as 
zoonosis. Numerous zoonoses have involved the human population since long time and possibly the more 
devastating example is represented by HIV, which causes the Acquired Immune Deficiency Syndrome (AIDS). 
Therefore, a deeper knowledge of retroviral biology is important to prepare a prompt response to the risk of 
zoonosis or recombination between different viruses [Locatelli and Peeters, 2012; Hahn et al, 2000 
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Retroviral transmission could be horizontal, meaning via cell-free virus or infected cells, or vertical occurring 
from parents to the offspring. Retroviruses can in fact occasionally integrate into the germ cells DNA, 
becoming Endogenous Retroviruses (ERV), as discovered in the late 1960s. The inheritance as Mendelian 
elements turned out to be the smartest and most cost-effective modality of viral transmission [revieweb by 
Stoye, 2012]. Phylogenetic studies report that genomes of all vertebrates species analyzed underwent 
multiple waves of “invasion” by retroviruses. The endogenous proviral genetic elements may be referred as 
"fossil" retroviral genomes, giving rise to an emerging field of evolutionary biology known as Paleovirology 
[reviewed by Stoye, 2012].  
ERVs represent about 8% of the human DNA, most of which are widely incorporated in old world monkeys, 
as proof of an early acquisition in primate evolution. In some animal species, a few ERV proviruses produce 
replication-competent viruses able to infect the same species or other species [reviewed by Stoye, 2012; and 
Weiss, 2013]. On the other hand, ERVs in humans appear also to be parasitic DNA sequences, exploited by 
the host as protection against further retrovirus infection. Their integration in the human genome could 
represent a potential risk of damage due to insertional mutagenesis and homologous recombination, but 
examples of disorders caused by an endogenous retroviral insertion into a gene reported in literature are 
rare [Villesen et al, 2004; reviewed by Stoye, 2012]. Most of human endogenous retroviruses (HERV) contains 
mutations preventing the production of infectious viral particles. However, a few open reading frames are 
preserved and some viral proteins may be produced. In 1995, Venables and colleagues reported the 
identification of a conserved human endogenous retroviral env gene expressed as glycoprotein in the human 
placenta differentiation [Mi et al, 2000]. HERV have been proposed as etiological co-factors in various 
diseases due to their enhanced expression in pathological conditions. Retroviral research is now focused on 
the possible HERV effects on host cell biology with particular regards in finding how HERV might contribute 
to diseases such as some kind of cancers and multiple sclerosis [reviewed by Stoye, 2012; Dolei et al, 2014; 
reviewed by Tugnet, 2013; reviewed by Bhardwaj and Coffin, 2014]. 
The ability of Retroviruses to be fixed and to cause a permanent modification into host cell genome can be 
exploited for therapeutic purposes. Retroviruses are promising tools to deliver and insert genetic information 
for replacement therapy in inherited disorders. The main concern for their use in therapy is the potential 
effect of insertional mutagenesis and the non-specific target cell recognition. The viral vectors can be 
properly engineered in order to avoid side effects and to optimize the desired target cell transduction. Apart 
from applications in gene therapy, viral vectors have also become important molecular biology tool to 
investigate gene functions [Bouard et al, 2009]. Over the last two decades, retroviral vectors have been 
extensively studied in order to improve their safety and efficacy. Remarkably, lentiviral vectors (LV) derived 
from infectious human retroviral isolates HIV-1 and HIV-2 (Human Immunodeficiency Virus 1 and 2 
respectively) have been accepted as the most promising gene delivery vehicles [reviewed by Naldini, 2015].  
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1.2  Retroviral classification and structure  
Retroviridae is a family of enveloped viruses, divided into two subfamilies Orthoretroviridae and 
Spumaretrovirinae. The former subfamily contains six genera known as α-retrovirus, β-retrovirus, γ-
retrovirus, δ-retrovirus, ε-retrovirus and lentivirus; while the latter consists of only spumavirus. This 
classification is based on the genetic relatedness of the Reverse Transcriptase ORF (Table 1) 
[reviewed by Voisset et al, 2008]. 
 
Table 1 Classification of Retroviruses. a Refers to exogenous retrovirus only. From Voisset et al, 2008, Microbiol Mol Biol Rev 72, 
157-196, table of contents. 
 
  
In addition, Retroviruses are broadly clustered into two groups according to their genome 
organization: “simple retroviruses” (α-retrovirus, β-retrovirus, γ-retrovirus and ε-retroviruses) and 
“complex retroviruses” (lentiviruses, δ-retroviruses and spumaviruses). Simple retroviruses contain 
just only three main structural genes (gag, pol-pro and env), while “complex” retroviruses express 
additional sets of genes with regulatory roles. A schematic representation of murine leukemia Virus 
(MLV) and human immunodeficiency virus (HIV) proviral genomes organization, as example of 
simple and complex retroviruses respectively, is reported in Figure 1. With reference to ERV, only 
those having a simple genome have become endogenous in their hosts (marked with a red asterisk 
in Figure 2) [Weiss, 2006].  
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Figure 2. Phylogeny of Retroviruses. Asterisks mark genera including endogenous genomes. From Weiss, Retrovirology, 2006, 3:67 
Figure 1. Retroviral genomes. Schematic representation of (A) MLV and (B) HIV-1 proviral genomes as examples of simple and 
complex retrovirus, respectively. Three main ORFs are reported in blue, the regulatory genes in red, the auxiliary genes in green and 
the regulatory regions in grey.  
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The retroviral genome consists of a single-stranded positive-sense RNA molecule, typically ranging 
between 7 to 12 kilobases in length, containing at least three main open reading frames (ORFs) 
(Figure 1): 
 group-specific antigen (gag) for core and structural proteins production, such as matrix 
(MA), capsid (CA) and nucleocapsid (NC) proteins (Figure 3); 
 protease-polymerase (pro-pol) expressing the viral enzymes reverse transcriptase (RT), 
protease (PR) and integrase (IN) (Figure 3); 
 envelope (env) encoding the surface (SU) and transmembrane (TM) domains of retroviral 
coat glycoproteins (Figure 3). 
In addition to these three genes, complex retroviruses encode accessory genes. For instance, the 
lentivirus HIV-1 encodes six accessory genes: vif, vpr, tat, vpu, rev and nef (Figure 1).  
Each viral particles has a diameter in the range of 80 to 120 nm determined by scanning transmission 
electron microscopy [Vogt & Simon, 1999]. A representation of the structure of a generalized 
retrovirus particle is reported in Figure 4. All the retroviruses show common virion components 
despite their differences in morphology and biology [Coffin et al, 1997]. The retroviral lipid envelope 
is reported to be enriched in sphingomyelin and cholesterol, suggesting that the viral budding occurs 
in correspondence of cholesterol-rich rafts at the cell plasma membrane [reviewed by Waheed and 
Freed, 2010]. 
Each virus particle is diploid, meaning that it contains two unspliced genome copies held together 
at the 5’ ends. Each RNA molecule is capped at the 5’ end and polyadenylated at the 3’-end. A 
complex splicing pattern ensures the expression of all retroviral ORFs. A splice donor (SD) and a 
splice acceptor (SA) sites are generally upstream of gag and env genes respectively (Figure 3). 
However, some retroviruses have additional splice sites. The RNA genome contains noncoding 
regions as well, important for its replication (Figure 3). At each end of the viral genome, there is a 
short repeated sequence known as R region, which is necessary to ensure correct end-to-end 
transfer in the growing chain during the reverse transcription. The repeated regions (R) are followed 
by “unique sequences” U5 and U3, at 5’ and 3’ ends respectively. Once converted into double 
stranded DNA, R, U5 and U3 regions form the long terminal repeats (LTRs), essential for provirus 
integration into the host. Another cis-acting sequence is the Primer binding site (PBS), where the 
annealing of a specific cellular transfer RNA (tRNA) takes place, to prime reverse transcription 
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(Figure 3) . Each retrovirus needs a specific tRNA as primer for reverse transcription, for instance 
HIV-1 adopts tRNALys while MLV uses tRNAPro.  
The 5’ LTR is followed by a region, called Ψ, acting as a signal for genome packaging into budding 
virions. Immediately upstream the U3 sequence there is a very important region for the synthesis 
of the positive-strand DNA in the reverse transcription process, called polypurine tract (PPT) (Figure 
3) [reviewed by Vogt, 1997]. Lentiviruses and some Spumaviruses contain an additional polypurine 
tract at the center of their genome (cPPT) together with a central termination sequence (CTS). In 
the reverse transcription process, this peculiarity results in the formation of a three stranded DNA 
structure called the central “DNA Flap”, that is of controversial functional significance [reviewed by 
Basu et al, 2008]. Further details about the reverse transcription process will be provided in the next 
paragraphs. 
 
 
Figure 3 Retroviral genome organization of its RNA and DNA forms. Abbreviations: R - repeated region at the ends of RNA genome; 
U5 and U3, unique elements close to the 5’ and 3’ ends respectively; PBS, primer binding site used for initiation of reverse 
transcription; Ψ - encapsidation signal; PPT – polypurine tract; SD - Splice donor site; SA - splice acceptor site. During reverse 
transcription, the LTR is formed, which contains gene promoter and enhancer elements. Four main genes are present in all infectious 
retroviruses,gag, pro-pol, and env. Retroviral proteins are synthesized as large polyprotein precursors and later cleaved into the 
mature viral proteins: matrix (MA), capsid (CA), nucleocapsid (NC), protease (PR), reverse transcriptase (RT), integrase (IN) and into-
the-surface (SU) and transmembrane (TM) envelope glycoproteins. Specific retroviruses encode additional proteins with specialized 
functions in the viral life cycle or pathogenesis. Adapted from Voisset et al, 2008, Microbiol Mol Biol Rev 72, 157-196, table of 
contents. 
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All retroviral proteins are synthesized as large polyprotein precursors, later cleaved into mature viral 
proteins by both viral (PR) and cellular proteases.  
Matrix (MA) proteins are associated with the lipid envelope through their N-terminal myristoylation; 
a post-translational modification important for assembly of retroviral particles [Bryant and Ratner, 
1990; Göttlinger et al, 1989]. Not all retroviral MA proteins are myristoylated, suggesting that 
additional factors are involved in its membrane targeting [Inlora et al, 2011]. Matrix proteins also 
interact with the TM domain of retroviral Envelope proteins during the budding step, an interaction 
which may promote Env incorporation into virions [Murakami and Freed, 2000; Wyma et al, 2000] 
but it is not essential [Briggs et al, 2003]. The capsid proteins (CA) form the core containing the viral 
genome associated with nucleocapsid proteins (NC). Mutations in a conserved cysteine and histidine 
motif of NC impair the packaging of the murine leukemia (MLV) genome into the nascent viral 
particles [reviewed by Rein, 2011]. Furthermore, depending on the type of retrovirus, other mature 
proteins may be produced from gag. For instance, murine leukemia virus (MLV) gag encodes an 
additional protein, p12, which seems to important for core stability and for tethering the pre-
integration complexes to mitotic chromosomes [Wight et al., 2014; Elis et al., 2012]. 
The protease enzyme (PR) converts the Gag-Pol polyprotein into functional proteins during the viral 
assembly and maturation steps. Reverse transcriptase (RT) is a RNA-dependent DNA polymerase, 
which uses the viral genomic RNA as template to synthesize a copy of the minus strand DNA. RT has 
also a ribonuclease H activity (RNase H), degrading the RNA strand in the newly synthesised hybrid 
RNA:DNA [Telesnitsky and Goff, 1997]. The plus strand DNA synthesis is carried out by the same 
enzyme using the undigested PPT (polypurine tract) as primer. Once synthesised the proviral DNA 
is delivered to the nucleus, where the viral integrase (IN) promotes its integration into the host 
genome. 
The proteins encoded by the env gene contain an N-terminal signal sequence allowing their delivery 
to the ER and subsequently to Golgi, where they are glycosylated and then cleaved by cellular 
proteases into two subunits: surface (SU) and transmembrane (TM). These subunits oligomerise into 
heterodimers, whose 3D structure determines the spikes on the viral envelope [reviewed by Eckert 
and Kim, 2001]. Being localized on the viral surface, the Env proteins establish the first virus-cell 
interactions and the entry of the virus into the host [Coffin, 1997].  
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Figure 4. Retrovirus particle structure. Abbreviations: NC – nucleopcapsid; MA – matrix; CA – capsid; SU – surface 
subunit of Env protein; TM – transmembrane subunit of Env protein; RT – reverse transcriptase; PR – protease; IN – 
integrase. From Thomás et al., 2013, Gene Therapy - Tools and Potential Applications, Chapter 12 - Lentiviral Gene 
Therapy Vectors: Challenges and Future Directions. DOI: 10.5772/52534. 
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1.3 Retrovirus replicative cycle 
As obligatory intracellular parasites, Retroviruses need a host cell to carry out their life cycle. They 
indeed can orchestrate host molecular mechanisms to achieve a proper replication. Since most of 
them are human and animal pathogen, a deep knowledge of their replication cycle is therefore 
needed for the development of proper antiviral therapies.  
The life cycle of retroviruses can be simply divided into two major distinct phases: the early phase 
going from the viral entry to the integration into the host cell genome, and the late phase covering 
the steps from the expression of viral genes to the release of mature progeny viral particles (Figure 
5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Steps in retroviral life cycle. The early phase of retroviral life cycle consists of: the binding of the virus to the target 
cell (1); the subsequent fusion between the host cell and the viral particle (2), the release of the viral content in the cytoplasm 
(3. Uncoating) and the simultaneous reverse transcription converting the viral single stranded RNA genome into double 
stranded DNA; the import of viral genome into the nucleus (4) and viral integration into the host genome(5). The late steps 
of retroviral life cycle include the expression of viral genome (6. Transcription) and the production of viral proteins (7. 
Translation), the subsequent assembly of viral particles (8) and their budding from the host cell (9). Once the virions are 
released from the host cells, they need to go through a further step known as maturation (10) to be properly infectious. 
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1.3.1 Binding 
The viral entry starts with the virus adsorption to the cell surface, mediated by viral glycoprotein 
and specific cell surface molecules interaction. The attachment process was thought to be 
dominated by a viral receptor, expressed by the host cell, recognizing viral glycoproteins. 
Conversely, other interactions came out to be important for virus binding [Sharma et al, 2000]. 
Reports about MLV and HIV-1 binding to target cells have shown the dispensable role of a specific 
receptor-Env interaction [Pizzato et al, 1999; reviewed by Ugolini et al, 1999], suggesting the 
involvement of other cell surface molecules like heparan sulfate proteoglycan [Mondor et al, 1998], 
LFA-1 [Fortin et al, 1998] and nucleolin [Nisole et al, 1999]. These additional attachment factors may 
be useful to concentrate the virus at the target cell surface in order to facilitate the subsequent 
specific receptor recognition [Pinon et al, 2003; Walker et al, 2002;]. Env or receptor-independent 
binding of HIV do not promote a productive infection [Schaeffer et al, 2004], which strictly requires 
Env binding to its cognate receptor. However, HIV can exploit its envelope glycoproteins interaction 
with lectins exposed on dendritic cells surface to get carried by these cells from peripheral sites of 
infection to lymph nodes. This way the infection in trans of target cells provided with the 
appropriate receptor can occur [Sewald et al., 2015]. This strategy is shared by many other viruses 
[reviewed by van Kooyk and Geijtenbeek, 2003] and by non-viral pathogens like Mycobacterium 
tuberculosis [reviewed by Montellaro et al, 2009]. 
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1.3.2 Entry 
The cell membrane represents at the same time the major obstacle and the strategic way to access 
the target cell for the infecting viruses. Retroviruses are able to employ a wide range of cell surface 
molecules to get the infection started. Membrane transport proteins such as CAT-1 for ecotropic 
MLV [Kim et al, 1991; Wang et al, 1991], GLUT-1 for HTLV, PIT-1 and PIT-2 for GaLV and amphotropic 
MLV respectively, and the T-cell surface marker CD4 for HIV [reviewed by Manel et al, 2005] are just 
few examples. This step of viral lifecycle is well characterized for HIV, which still represents a 
significant public threat. Initially, the interaction between envelope glycoprotein surface subunit 
gp120 and CD4 receptor takes place, leading to conformational changes and the subsequent 
recruitment of coreceptors belonging to the chemokine receptor family (CXCR4 and CCR5) 
[reviewed by Berger et al, 1999]. The envelope glycoprotein gp120 then associates to the 
coreceptors and performs a further conformational shift [Kwon et al, 2014]. This set of structural 
modifications causes the dissociation of the surface subunit gp120 from gp41 and the subsequent 
exposure of the fusion peptide that accounts for the fusion of viral and cellular membranes [Gallo 
et al, 2003; Moore et al, 2003]. This process is energetically unfavourable and requires the 
destabilization of the membrane microenvironment [Cohen and Melikyan, 2004]. As a result, the 
formation of a fusion pore allows the viral core to be released into the cytosol. [Gallo et al, 2003; 
Moore et al, 2003].  
The direct fusion with the host cell plasma membrane is the entry route observed for many 
retroviruses like HIV (Figure 6 B) [McClure et al, 1988]. However, more recent studies have shown 
that HIV infection occurs after internalization into intracellular vesicles [Miyauchi et al, 2009; Carter 
et al; 2011; de la Vega et al 2011; Maréchal et al, 2001]. Taken together, these reports suggest that 
HIV particles may be internalized into the target cell by endocytosis and their release into the host 
cytoplasm is pH independent, as it takes place at early endosomes without requiring endosome 
acidification (Figure 7A). The acidic late endosome can actually activate proteases degrading the 
viral particles. A receptor-independent binding of HIV virions may promote its entry via endocytosis 
as well [Schaeffer et al, 2004]. In this case HIV entry is pH dependent, as the virus has to compete 
with degrading proteases into the late endosome to reach the cytoplasm (Figure 7B) [Yoshii et al, 
2011]. However, CD4-independent entry pathway leads to a less productive infection compared to 
the CD4-dependent one [Fredericksen et al, 2015].  
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Since the degradation of the endocytosed components into acidic intracellular compartments is part 
of a cellular innate immune response to external threats, the CD4-dependent HIV entry might be 
evolved from the CD4-independet one, in order to overcome the late endosome degradation. The 
virus adaptation to use cellular immune reactions to get into the cells has revealed a great strategy 
to avoid host immune defence. 
Figure 6. Virus entry strategies. Viruses have evolved various strategies to overcome the barriers imposed by the target cell, such as 
receptor-mediated endocytosis followed by pH-dependent/ independent fusion from endocytic compartments (A) or pH-
independent fusion at the plasma membrane, coupled with receptor-mediated signaling and coordinated disassembly of the actin 
cortex (B). Non-enveloped viruses use similar strategies, although the mechanisms of action are different. Adapted from Grove and 
Marsh, 2011, JBC. 
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Some other retroviruses follow the endocytosis pathway to infect the target cells although through 
different mechanisms. For instance, avian leukosis virus (ALV) and equine infectious anemia virus 
(EIAV) require clathrin-mediated endocytosis [Brindley et al, 2005; Jin et al, 2005]; while 
amphotropic MLV and Ebolavirus have been recently identified to entry the target cells via 
macropinocytosis [Rasmussen and Vilhardt, 2014]. Retrovirus are actually able to exploit different 
internalization pathways for productive infection, like phagocytosis, macropinocytosis or clathrine-
mediated endocytosis. However, the type of target cells may determine the viral preferential entry 
pathway and the eventual requirement of endosome acidification as well. 
 
 
Figure 7. Entry pathway of CD4-dependent (panel A) and CD4-independent (panel B) HIV. Blue area indicates acidic conditions. 
Adapted from Kubo et al, 2012, Advances in Virology, 640894 
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Retroviruses may enter the host cell through specific membrane microdomains known as “rafts”. 
They are made up of sphingolipids and cholesterol packed together in ordered, rigid and mobile 
structures [Brown and London, 2000; Lee, 2001]. and they may work as docking sites for proteins 
involved in processes like signalling or endocytosis [Alonso and Millan, 2001; reviewed by Simons 
and Toomre, 2001; Simons and Ehehalt, 2002]. Experimental data, arguing for a role of lipid rafts in 
retroviral entry process, show the clustering of both viral envelope glycoproteins [Bavari et al, 2002; 
Pickl et al, 2001] and cellular receptors in these membrane domains [ Popik et al, 2002]. 
The retargeting of either envelope glycoproteins [Rousso et al, 2000] or cellular receptors to non-
raft membranes may impair viral entry [Del Real et al, 2002]. Moreover, lipid components of cell 
membrane rafts, like some glycosphingolipids, may interact with viral envelope glycoprotein acting 
as alternative entry co-factors [Hug et al, 2000]. In addition, cholesterol depletion in target cells 
prevents HIV-1 infection and syncytium formation [Manes et al, 2000; Liao et al, 2003]. On the other 
hand, controversial reports question the actual role of lipids in retroviral entry. For instance, some 
studies have demonstrated that HIV entry is not affected by CD4 and CCR5 localization into non-
rafts membrane domains [Percherancier et al, 2002; Popik and Alce, 2004]. Additionally, the effect 
of cholesterol depletion on HIV-1 infectivity may be rescued by an increasing expression of CD4 and 
CXCR4 molecules [Viard et al, 2002]. 
 In summary, it remains unclear whether membrane rafts act as concentrating platforms of factors 
modulating the entry process and further studies are required to better characterize and clarify lipid 
domains implications into retroviral biology. 
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1.3.4 Uncoating  
Upon the fusion between the viral and cellular membranes, the viral core is released into the 
cytoplasm where it starts disassembling into subviral particles, called reverse-transcription 
complexes (RTCs) and pre-integration complexes (PICs).  
The uncoating is a gradual multi-steps process, starting with the initial break of HIV-1 capsid [Yu et 
al, 2013] followed by its complete dissociation [Jun et al., 2011, Xu et al., 2013). Recent studies have 
demonstrated that capsid stability is required for reverse transcription process, supporting the idea 
that the two processes are mechanistically coupled [reviewed by Ambrose and Aiken, 2014]. CA 
reduced stability is often linked to a reduced reverse transcription and decreased infection [Rihn et 
al., 2013; von Schwedler et al., 2003].  
Recent in vivo imaging show the uncoating as a process taking place just before the end of reverse 
transcription [Hulme et al., 2011; Xu et al., 2013] suggesting that the DNA synthesis and the 
uncoating are simultaneous events. However, the uncoating steps is necessary to allow some 
cellular factors to take part to the retrotrascription process [Warren et al., 2012; Warrilow et al., 
2009]. In 2011, Hulme and colleagues supported the hypothesis of the induction of the uncoating 
by reverse transcription itself, as inhibition of reverse transcription turns into a delay in core 
disassembling as consequence of the increased core stability [Yang et al, 2012]. 
HIV-1 uncoating is a strictly monitored process based on a proper capsid stability and interaction 
with multiple host factors. Premature or delayed dissociation of capsid may affect reverse 
transcription and nuclear import resulting in abortive infection. The incoming viral particles have 
evolved specific mechanisms to interact with host molecular partners in order to facilitate their 
journey through the cytoplasm with nuclear destination. In particular, cellular cytoskeleton proteins 
seem to play an important role for the uncoating step of different viruses [Ploubidou and Way; 
2001]. Another host protein fundamental for viral uncoating is cyclophillin A (CypA), which directly 
binds the capsid and gets incorporated into nascent viral particles [Luban et al, 1993; Thali et al, 
1994; reviewed by Ambrose, 2014]. Lacking of CypA or impaired binding between CypA and capsid 
upon the treatment with cyclosporine A (CsA), result in a defective disassembly of the HIV-1 core 
[Braaten et al, 2001]. Actually, CypA role consists of protecting HIV-1 capsid by the human restriction 
factor TRIM5α action [Towers et al, 2003; Hatziioannou et al., 2004) Stremlau et al, 2004], and by 
the innate sensing [Rasaiyaah et al., 2013], thus increasing HIV-1 infectivity.   
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Among the host protein interacting with capsid there are CPSF6 [Henning et al., 2013], which is 
involved in mRNA processing and shuttles between nucleus and cytoplasm, the transportin TNPO3 
and the nucleoporines NUP358 and NUP153 [Price et al, 2012] which allow the delivery of PICs 
through the nuclear membrane. The association of CA ultrastructures with NPCs and the nuclear 
envelope reported by Arhel and colleagues in 2007, suggests that uncoating takes place mainly at 
the nuclear periphery upon completion of reverse transcription. Although the role of host factors 
during the uncoating step is still poorly understood, it is possible that the process takes place in 
proximity of nuclear pore just to promote a safe delivery of viral contents into the nucleus of the 
infected cell [Rasaiyaah et al., 2013].  
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1.3.5 Reverse transcription 
Although there is evidence showing DNA synthesis in virions before infection [Lori et al, 1992; 
reviewed by Coffin et al, 1997; Davis et al, 2008] and during the uncoating step [Zhang et al, 2000], 
reverse transcription usually takes place in the cytoplasm in parallel with the release of the viral 
core. Upon fusion with the target cell, the virus starts reverse transcribing its genome inside a 
ribonucleoparticle complex known as reverse transcription complex (RTC) [Fassati and Goff, 2001]. 
The only exception is represented by Foamyvirus virions, in which the retroviral genome is already 
found almost completely reverse transcribed [Zamborlini et al, 2010]. In all other cases studied so 
far, the viral RNA is reverse transcribed in the target cell cytoplasm by the virion-packaged reverse 
transcriptase (RT). This process might be stimulated by the high concentration of 
deoxyribonucleotides in the cytoplasm [reviewed by Goff, 2001]. 
The viral RT enzyme starts the polymerization of a minus-sense DNA strand using the RNA genome 
as template and the 3’ end of a cellular tRNA as primer annealed at the primer binding site (PBS) 
(Figure 8-A). Each retrovirus uses a specific tRNA, for instance HIV-1 adopts tRNALys while MLV uses 
tRNAPro. Once the 5’ end of the viral RNA template is reached (Figure 8-B), the RT uses its 
ribonuclease H activity (RNase H) to degrade the genomic RNA strand in the newly synthesised 
hybrid RNA:DNA (Figure 8-C). The correct end-to-end transfer of the growing minus-strand DNA 
chain is governed by the repeated region (R) matching (Figure 8-D), so that RT can carry on the 
synthesis of the minus-strand DNA and the progressive digestion of the RNA template (Figure 8-E). 
The polypurine tract region (PPT) of the viral RNA genome is resistant to RNase H degradation, and 
therefore is used as primer for the plus strand DNA synthesis (Figure 8-F). The complete 
polymerization of the plus-strand DNA until the portion of the tRNA primer allows its removal 
(Figure 8-G). The plus-strand DNA is then transferred to the opposite site of the minus-strand DNA 
template to allow the annealing of PBS regions (Figure 8-H). At this point the synthesis of both 
strands is completed, resulting in a linear double stranded DNA molecule flanked by two long 
terminal repeats (LTR) (Figure 8-I) [Telesnitsky and Goff, 1997].  
30 
 
 
Figure 8. The reverse transcription process. A detailed description of the process is provided in the text. 
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Lentiviruses and some Spumaviruses contain an additional polypurine tract in the center of their 
genome (cPPT) together with a central termination sequence (CTS). During reverse transcription, 
the positive DNA strand is produced into two halves initiated from the two different polypurine 
tracts respectively, resulting in the formation of an unusual three stranded DNA structure known as 
“DNA Flap” in Lentiviruses and “DNA gap” in Spumaviruses (Figure 9) [Zennou et al, 2000]. 
 
 
Figure 9. The central DNA FLAP generated by HIV-1 reverse transcription. Taken from Nisole and Saib, 2004, 
Retrovirology. 
 
DNA plus-strand extension from the cPPT primer may slow down reverse transcription rate inside 
the cell [Riviere et al, 2010; Skasko and Kim, 2008]. Thus resulting into a kinetic advantage conferred 
by cPPT  since the viral single stranded DNA is less exposed to the in inhibitory activity of APOBEC3 
cytosine deaminase restriction factors [Hu et al, 2010], and the RTC/PIC are more protected from 
other host defense proteins action[Poeschla et al, 2013]. 
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1.3.6 Nuclear Import   
 
Once synthesised, the viral DNA is associated with some viral proteins forming PICs (pre-integration 
complexes). These complexes need to overcome the nuclear membrane barrier in order to get the 
viral DNA integrated into host genome. For most retroviruses, like MLV, PICs may access the host 
genome only during cellular mitosis, due to their inability to enter intact nuclei [Roe et al, 1993; 
Lewis and Emerman, 1994]. These retroviruses are therefore unable to replicate in non-dividing 
cells. On the other hand, PICs form Lentiviruses are able to cross the nuclear membrane [Bukrinski 
et al, 1992] resulting in infection of non-proliferating cells, like macrophages or quiescent T-
lymphocytes [Gartner et al, 1986; Weinberg et al, 1991]; whereas Foamyviruses are able to replicate 
in both dividing and non-dividing cells [Bieniasz et al, 1995; Saib et al, 1997]. In order to cross the 
nuclear membrane, lentiviral PICs need to interact with the nuclear pore complexes (NPCs), made 
up of 30 different nucleoproteins (NUPs) crossing the nuclear membrane and connecting cytoplasm 
and nucleoplasm [Hoelz et al, 2011]. The transport through the nuclear membrane is governed by 
the size of the NPCs and by the protein-protein interactions between NUPs and specific carrier 
proteins [Conti et al, 2006; Terry et al, 2009]. The directionality of trans-nuclear trafficking is 
regulated by the gradient of Ran (Ras related nuclear) GTPase proteins, which binding protein carrier 
with different affinity according to their association with GTP/GDP (guanosine triphosphate/ 
guanosine diphosphate) [Nemergut et al, 2001; Saitoh et al, 1997]. Usually, the RTCs/PICs (reverse 
transcription/pre-integration complexes) observed in the cytoplasm are larger than the nuclear 
pore diameter [Lelek et al, 2012; McDonald et al, 2002]. The core of the PIC driving integration is 
made up of double-stranded reverse-transcribed viral DNA and a tetramer of IN proteins and it is 
known as intasome [Li et al, 2006; Hare et al, 2010] 
With reference to HIV, the viral nucleoprotein complexes are made up by integrase (IN), matrix 
(MA), Vpr, NC, RT, PR proteins and the viral DNA [Iordansky et al, 2006, Bukrinsky et al, 1993; Gallary 
et al, 1997; Heinzinger et al, 1994]. Recent microscopy reports have identified also CA as part of 
cytoplasmic nucleoprotein complex [Lelek et al, 2012; McDonald et al, 2002]. Indeed, CA viral 
protein was found to be a master regulator of HIV-1 nuclear import. Chimeric HIV-1 viruses 
expressing MLV CA were no more able to replicate in non-dividing cells [Yamashita and Emerman, 
2004]. Interestingly, some CA mutants impaired in infectivity showed a post-entry defect [Yamashita 
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et al, 2007] while others proved a defect at the level of nuclear import itself upon a delayed 
uncoating [Dismuke et al, 2006]. 
A set of shuttling receptors known as importins [Gallay et al, 1997; Ao et al, 2010], mediate the 
nuclear import through the recognition of a nuclear localization signal (NLS), a short amino acidic 
sequence that marks the protein for nuclear delivery [reviewed by Fried and Kutay, 2003]. Recent 
findings have shown a direct interaction between IN and transportin 3 (TNPO3) [Larue et al, 2012; 
Christ et al, 2008] and to nucleoporins like NUP153 [Woodward et al, 2009], thus avoiding the 
involvement of a molecular adaptors. While PICs protein components show different kinds of NLS 
mediating their interaction with NPCs elements with differential strenght [reviewed by Sherman 
and Greene, 2002], a crucial role for HIV-1 PIC nuclear import could also be played by the viral DNA 
structure itself.  
As mentioned previously, in Lentiviruses the reverse transcription leads to the formation of a 
particular DNA structure known as “DNA flap” (Figure 9). This structure has been defined as a cis-
determinant of its own efficient nuclear import [Zennou et al, 2000]. Interestingly, DNA flap 
structure was observed to play a role in proviral integration as well [Van Maele et al, 2003]. Although 
this structure could be dispensable for integration [Marsden et al, 2007], some recent findings have 
shown its positive  effect on viral replication [De Rijck et al, 2006; Riviere et al, 2010; Ao et al, 2004]. 
So far, microscopy-based approaches have provided important tools to detect HIV-1 nuclear import 
and integration [Lelek et al, 2012; Christ et al, 2008; Di Primio et al, 2013] but live-cell tracking 
strategies for nuclear import are still missing. 
 
 
 
 
 
 
 
 
34 
 
1.3.7 Integration 
 
Following nuclear import, the viral DNA integrates as a provirus, flanked by the long terminal repeat 
(LTR). As part of the host genome, the viral DNA may be passed on to progeny cells. This singular 
feature of retroviruses allows them to keep the genetic information life-long in the cell-genome. 
The integrase (IN) enzyme is the key factor mediating this step. It not only accounts for the viral DNA 
integration itself, but it also determines the site of integration, together with cellular partners taking 
part to the process. IN cleaves the 3’ ends of each LTR of viral DNA, thanks to its nuclease activity, 
then it catalyses the formation of phosphodiester bonds between the target cellular DNA and the 
viral DNA through its DNA binding and transesterification activities. These events turn the RTC into 
PIC complex [reviewed by Krishnan and Engelman, 2012]. Conventionally cellular proteins involved 
in the DNA damage response fills in the nicks and gaps flanking the viral DNA [reviewed by Smith 
and Daniel, 2006]. The integration and the consequent expression of viral DNA might be affected by 
the chromatin architecture of the flanking cellular sequences [Pryciak et al, 1992]. For instance, MLV 
integration targets actively transcribed genes [reviewed by Craigie, 1992]; mainly in the proximity 
of the gene transcriptional start sites and CpG islands [Moalic et al, 2006; Wu et al, 2003]. HIV and 
SIV integration occurs in highly expressed genes as well, but unlike MLV it is found along the 
transcriptional unit [Wu et al, 2003; Schroder et al, 2002]. On the other hand, ALV does not integrate 
in transcriptionally active regions. The integration site choice might also rely on host cell proteins 
interacting with viral IN and PICs factors. For HIV, several host IN binding partners have been 
identified to take part to the integration process. LEDGF (lens epithelium-derived growth factor) and 
HMG-I (Y) (high mobility group proteins) are two examples of host proteins that seem to stimulate 
HIV DNA integration through their direct interaction with IN [Maertens et al, 2003; Cherepanov et 
al, 2003; Farnet and Bushman, 1997; Li et al, 2000]. 
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1.3.8 Viral RNA synthesis and processing 
After the integration, the viral DNA mimics a cellular gene and its expression is carried out by the 
host-cell transcriptional machinery including RNA polymerase II and its transcription factors. The 
transcription process is orchestrated by the viral cis-acting elements, localized in the viral DNA non-
coding regions (Figure 3). The long terminal repeats (LTRs) contain an enhancer sequence (U3), 
binding sites for host transcription factors and regulating transcriptional initiation by cellular RNA 
polymerase II [Speck and Baltimore, 1987]. Moreover, the promoter in the U3 region contains the 
TATA element upstream the transcription start site [Wilson et al, 2003]. Each retrovirus employs a 
specific repertoire of transcription factors depending on the target cell. The complex retroviruses 
(like HIV and HTLV) express their own transcriptional activators and regulators (Tat and Tax 
respectively), which provide the virus with additional gene expression control. The cis-acting 
elements in 3’ LTR are involved in the post-transcriptional processing of the RNA products. This step 
is carried out by host the RNA processing machinery, which provides each RNA molecule with a 5’ 
end cap and a polyadenylated tail at the 3’ end. During retroviral replication, part of the full-length 
viral RNA transcripts are subsequently packaged into budding virions as genomic RNA, while 
subgenomic-sized RNA molecules may be produced by alternative RNA splicing. Both genomic- and 
subgenomic-sized RNAs may function as mRNA for viral proteins production [Rabson and Graves, 
1997].  
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1.3.9 Nuclear export  
Retroviruses have to face the critical task of exporting their unspliced RNAs from the nucleus to the 
cytoplasm. In simple retroviruses this step relies on cis-acting sequences, while in complex 
retroviruses the presence of accessory proteins can provide for nuclear export. Gag proteins from  
RSV, FIV, and PFV interact with the cellular CRM1 protein for nuclear export [Kemler et al, 2012; 
Renault et al, 2011]. In Moloney MLV (MoMLV) the packaging signal can account for this function 
[Smagulova et al, 2005], while in HIV-1 the regulatory protein Rev can act as adaptor between the 
viral RNA and the nuclear export protein [reviewed by Polland and Malim, 1998]. Rev protein 
multimerize on the RNA molecules and recruits cellular cofactors like h CRM [[Daugherty et al, 2010; 
Chaytania and Belasco, 2001]. Rev and the RRE-containing viral are transcripts both found into the 
nucleolus, suggesting a possible nucleolar step of the Rev-RRE complex necessary for nuclear export 
[Michienzi et al, 2000; Buonomo et al, 1999; Fischer et al, 1999]. Recent reports have shown a co-
localization of Rev with HIV-1 RNA at the transcription sites, supporting the idea that Rev binds the 
transcripts co-transcriptionally [Kula et al, 2013]. HIV-1 RNA export takes place thanks to the 
presence of nuclear export signals in Rev proteins mediating its interaction mainly with 
CRM1/RanGTP export complex and a subset other cellular proteins involved [Kula et al, 2013; Naji 
et al 2012; Nekhai and Jeang, 2006; Hadian et al, 2009]. Interestingly, the nuclear matrix-associated 
protein Matrin 3 is reported to be an important co-factor for HIV-1 RNA export. Matrin 3 binds HIV-
1 RNA cotranscriptionally and it generally increases cellular mRNA stability; however the mechanism 
by which facilitates Rev-mediated nuclear export of unspliced RNA is still poorly understood [Kula 
et al, 2013; Yedavalli et al, 2011; Salton et al 2011]. Recent reports have shown how nuclear matrix 
components form tubular pathways connecting genomic DNA and nuclear pore complexes for 
nuclear export of transcripts [Malecki and Malecki, 2012]. Being a nuclear matrix-associated protein, 
Matrin 3 might act as a bridge between Rev and active HIV-1 RNA transcription sites, recruiting all 
the cellular factors needed like CRM1 nuclear export machiner [Yedavalli et al, 2011; Kula et al, 
2013]. Other complex retroviruses encode Rev-like proteins that can account this role [Indik et al, 
2005; Mertz et al., 2005]. 
 
  
37 
 
1.3.10 Assembly 
Assembly is a highly dynamic process and follows different routes for different retroviruses. For 
lentiviruses, α- and γ-retroviruses assembly takes place at the plasma membrane where all viral 
components are delivered, whereas β- and δ–retroviral cores are assembled in the cytoplasm and 
subsequently move to the cell membrane proximity [Swantstrom and Willis, 1997].  
Lipid rafts in the plasma membrane work as a meeting point for the transmembrane and core 
components to assemble the viral particle. As a result, viral particles incorporate both the envelope 
components as well as constituents of host cell lipid rafts, like gangliosides, cholesterol and lipid-
anchored proteins. Many viruses are reported to assemble in correspondence of specific rafts 
domains, which associate with the specific budding site of the viruses. For instance, the apical 
targeting of influenza virus hemagglutinin (HA) and neuroaminidase (NA) envelope glycoproteins 
correlates with the apical budding of the virus itself [Scheiffele et al, 1997; Simons and Ikonen, 
1997]. The same has been reported for vesicular stomatitis virus (VSV), whose G glycoprotein 
expression in rafts has a basolateral localization corresponding with its preferential budding site 
[Pickl et al, 2001]. The assembly of measles virus within membrane rafts has been demonstrated 
too [Manie et al, 2000; Vincent et al, 2000]. Additionally, HIV-1 lipidic envelope composition strongly 
support its assembly and subsequent budding from lipid rafts [Briggs et al, 2003; Ono and Freed, 
2005]. 
For HIV-1, Gag polyprotein production strategy orchestrates the assembly process, since it facilitates 
the targeting of each components to the assembly site. In the cytoplasm, the ribosomes synthesize 
the Gag polyprotein precursors Pr55gag and Pr160gag-pol (Figure 10), from the same unspliced viral 
RNA. These protein precursors are cleaved by the viral protease during or after assembly of the viral 
particle, leading to the maturation of an infectious virion. On the other hand, spliced RNA transcripts 
are used to synthetize Env proteins on the membrane of the RER (rough endoplasmic reticulum), 
where they are firstly produced as a single polypeptide (gp160), glycosylated and then cleaved by a 
cellular protease into surface (gp120) and transmembrane (gp41) subunits. Vesicular transport 
drives the viral glycoproteins through the Golgi apparatus to the plasma membrane. Once on the 
cell surface they move towards the budding site for viral core packaging [Swantstrom and Willis, 
1997], clustering all together in membrane rafts [Bavari et al, 2002; Manie et al, 2000; Pickl et al, 
2001]. The plasma membrane localization and the recruitment of Envelope glycorpoteins are 
regulated by MA (Figure 10) [Bryant and Ratner, 1990; Göttlinger et al, 1989; Rein et al, 1986]. CA is 
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the Gag protein central domain and it mediates interactions among proteins required to create the 
viral protein shell. Interestingly, CA C-terminal domain is conserved across different retroviruses 
confirming its particular importance in immature particle assembly [von Schwedler al, 2003]. The 
Gag basic C-terminal domain NC contains two zinc finger motifs used to capture the viral RNA dimer 
during assembly. Finally, an additional C-terminal protein (p6) binds several protein partners, 
including the accessory viral protein Vpr [reviewed by Sundquist and Krausslich, 2012]. Furthermore, 
HIV-1 accessory protein Nef is targeted to the inner leaflet of the membrane rafts through its N-
terminal myrystoylation, although it is not a structural protein per se. Nef therefore gets 
incorporated into the viral particles [Welker et al, 1998], but whether its incorporation plays any 
role remains unclear [Wang et al, 2000; Zheng et al, 2003]. A model for HIV-1 assembly and budding 
through membrane rafts is reported in figure 11.  
 
 
 
 
Figure 10. Linear organization of the HIV-1 Gag polyprotein precursors. The myristylated matrix (MA), capsid (CA), nucleocapsid 
(NC) and p6 domains are codified by Pr55gag precursor (A). Protease (PR), Reverse transcriptase (RT), RNaseH (RH), Integrase (IN) 
domains are expressed by Pr160gag-pol precursor (B). Red arrows indicate sites of PR processing. PR cleavage produces p2 and p1 
residues in Pr55gag precursor, whereas Transframe peptide (TF) in Pr160gag-pol precursor. Adapted from Tözsér, 2010, Viruses, 2, 147-
165 
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Figure 11. HIV-1 assembly and budding through membrane rafts. gp160 trimerizes inside the ER, then it gets associated to the rafts 
and migrates to the plasma membrane. Pr55gag and Pr160gag-pol oligomerize around two genomic RNAs and are anchored to the 
plasma membrane rafts due to the myristoylation of the MA domain. This allows the binding of MA to the cytoplasmic tail of 
glycoproteins. The cytoplasmic Nef protein, after palmitoylation, associates with the inner leaflet of the plasma membrane raft 
resulting in Nef incorporation into HIV-1 particles and in the enrichment of the envelope in lipid rafts. Then HIV-1 virion buds from 
the plasma membrane rafts and undergoes to maturation following the of Gag precursors. Once incorporated into the viral particle, 
Nef is partly cleaved off by the viral protease into a soluble domain, which is thought to bind to the RNP. Membrane rafts are reported 
in grey regions within the lipid bilayer.From Chazal and Gerlier, 2003, Microbiol. Mol. Biol. Rev, 67, 226-237. 
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1.3.11 Virions budding and maturation 
The budding steps consist in the release of the virions from the plasma membrane [Garroff et al, 
1998]. Assembly of the immature viral core induces a local curvature of the membrane adopting a 
dome-shaped structure. This event is followed by the formation of a lipid stalk and its final fission. 
The association of lipid rafts in the assembly step suggests their possible involvement in the budding 
process of different retroviruses like influenza and HIV-1 [reviewed by Chazal and Gerlier, 2003]. 
Moreover, lipid analysis of viral envelopes shows an enrichment of raft-lipids, supporting their 
budding from raft domains [Takeda et al, 2003; Brugger et al, 2005; Nguyen, 2000]. 
HIV-1 and many other enveloped viruses, like Ebola virus, VSV and rabies [Freed, 2002; reviewed by 
Chazal and Gerlier, 2003], exploit the host ESCRT (endosomal sorting complexes required for 
transport) machinery to catalyse virions release. ESCRT factors are able to facilitate membrane 
fission, in fact they are employed by the cells in mechanisms like endosomal vesicles release or 
cytokinesis [Morita and Sundquist, 2004; Beniasz, 2009; Carlton and Martin-Serrano, 2009; Usami 
et al, 2009; Hurley and Hanson, 2010; Peel et al, 2011]. HIV-1 Gag polyprotein precursor Pr55gag 
plays a leading role in this phase too, since its p6 domain recruits motifs ESCRT factors [Pornillos et 
al, 2003]. The internal appearance of all immature retroviral particles is fundamentally the same 
and characterized by spherical structures with an electron-lucent center. 
Viral maturation takes place almost simultaneously with the budding process. PR is activated and 
cleaves the Gag polyprotein precursors Pr55gag and Pr160gag-pol into their fully processed constituent 
proteins [Swanstrom and Wills, 1997; Hill et al, 2005]. The events triggered by Gag proteolysis 
include the condensing of viral RNA genome and the rearrangement of the capsid into a canonical 
shape. These processes mark the conversion of an immature non-infectious virion into a mature 
one, ready to enter and replicate in a new host cell. Foamyviruses represent an exception, since 
they retain an immature morphology [Swanstrom and Wills, 1997]. 
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1.4 Retroviruses and human diseases 
Retroviruses include many human pathogens able to cause a wide variety of malignant, 
immunological and neurological diseases [Coffin et al, 1997; Goff, 2000]. Human T-lymphotropic 
virus type 1 (HTLV-I) was the first to be discovered in 1980 [Poiesz et al, 1980]. It is reported to cause 
cancer and neurodegeneration [Barmak et al, 2003]. Few years later, another subtype of human T-
cell leukemia virus (HTLV-II) was discovered to be associated with a variant T-cell leukemia 
[Kalyanaraman et al, 1982]. A particular scientific attention has been focusing on the causative 
agents of the pandemic acquired immunodeficiency syndrome (AIDS): the human 
immunodeﬁciency viruses types 1 and 2 (HIV-1 and HIV-2) identiﬁed in 1983 and 1986, respectively 
[Barr’e-Sinoussi et al., 1983; Clavel et al., 1986]. 
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1.5 HIV  
1.5.1 Origins 
Molecular phylogeny studies have demonstrated that HIV-1 and HIV-2 are the result of cross-species 
transmissions of lentiviruses infecting African non-human primates. These viruses are known as 
Simian Immunodeficiency Viruses (SIVs) which naturally infect their host primate specie without 
inducing pathogenesis. Interestingly, in 1987 a study reported the evolutionary relationship 
between HIV-2 and SIVsm, a non pathogenic virus in sooty mangabeys [Chakrabarti et al, 1987; 
Guyader et al, 1987] (Figure 12).  
 
Figure12 .Origins of human AIDS viruses. From Sharp and Hahn, 2011, Cold Spring Harbour Perspect Medicine; 1 
 
Further studies identified a close phylogenetic correlation between HIV-1 and SIVcpz [Huet et al, 
1990] and later it was demonstrated that SIVmac, causing immunodeficiency in macaques, had been 
actually generated by a zoonotic transfer of SIVsm [Apertei et al, 2005]. Taken together these results 
suggested that cross-infections events of lentiviruses from different primate species had led to the 
development of AIDS in both humans and macaques [Sharp et al, 1994] 
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HIV-1 and HIV-2 are both complex Retroviruses belonging to the subfamily of Lentiviruses. A 
schematic representation of HIV life cycle is reported in Figure 13. 
 
 
Figure 13. HIV-1 life cycle. From Rambaut et al.,2004, Nature Reviews Genetics, 5, 52-61 
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 1.5.2 AIDS Pathogenesis 
If not treated, HIV-1 infection leads to a pathological condition known as AIDS (Acquired Immune 
Deficiency Syndrome), characterized by a massive decrease of CD4+ T cells number with the 
consequent instauration of many lethal opportunistic infections. The fast HIV-1 evolution within the 
host has conferred a pandemic trait to the disease, which currently still affects 36.9 million people 
in the world [2014 global statistics UNAIDS]. Currently, there is no region of the world unaffected 
by this pandemic (figure 14). However, the remarkable amount of information collected in about 30 
years of research studies has provided the AIDS patients with better life expectancy and quality 
despite the lack of an eradication therapy.  
 
 
 
Figure 14. Global estimation of HIV infected people worldwide. From UNAIDS, July 2015, Core Epidemiology Slide. 
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The infection process (Figure 15) starts with the virus entry into the target host cell, from which it 
keeps spreading and replicating without causing any visible symptoms or immune reaction for the 
first 2 weeks after the first infection event. This step is then followed by an acute phase 
characterized by high levels of viraemia, activated immune response and the manifestation of “flu-
like” symptoms. At the end of this acute phase, the level of viraemia declines dramatically because 
of the partial control by the immune system and the decline in the numbers of CD4+ T cells available 
for infection. The following stage is known as “clinical latency”, a time of variable length (from 1 to 
20 years) where the patients are asymptomatic and usually unaware of their condition. On the other 
hand, the virus is not latent since it keeps infecting new CD4+ T cells constantly and slowly. When 
the number of CD4+ T cells declines over a threshold value (about 200 cells/l), the host immune 
system is unable to face external threats and opportunistic infections become out of control 
[Lackner et al. 2011]. The level of viremia rises as well, becoming lethal for the infected individuals. 
Among all infectious disease, AIDS is therefore the one with the highest mortality rate (over 95%) 
[Coffin and Swanstrom, 2013].  
 
 
Figure 15. Time course of HIV-1 infection. From Fauci and Desrosiers, 1997. Cold Spring Harbor Laboratory Press, Cold 
Spring Harbor (NY) 
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The availability of sensitive and accurate tools to detect viraemia is important not only for diagnosis 
but also for prognosis purposes. Available assays are based on the detection of HIV-1 genomic RNA 
in blood samples by PCR and on the detection of HIV-specific antibodies. The level of virus detected 
in the blood indicates the damage rate of host immune system by viral infection [Mellors et al, 1996] 
and it is predictive of transmission risk [Quinn et al, 2000; Wawer et al, 2005]. Moreover, these kind 
of clinical assays are also indicative of the efficiency of a specific antiviral therapy. Remarkably, the 
current treatment strategies [Arts and Hazuda, 2011] have revealed a kind of viral persistence after 
a prolonged therapy, showing the necessity for lifelong therapy. Indeed, as soon as the therapy is 
suspendend, the level of viraemia rapidly increases, despite the prolonged suppressive treatment 
[Palmer et al, 2008]. Since the level of viraemia reflects the number of virus-producing cells [Coffin, 
1995], this phenomenon was explained through the identification of a pool of cells acting as viral 
reservoir and insensitive to the treatment [Siciliano and Green, 2011]. This pool of latently infected 
cells is characterized by a longer lifetime and by the ability to produce viral particles after ex vivo 
stimulation. However, they represent just only a small fraction compared to the population of 
productively infected cells in chronic infection [reviewed by Coffin and Swanstrom, 2013]. The 
“protection” of these cells from the antiviral treatment could be explained by the less accessibility 
of the virus as confined to anatomic sites, defined as “sanctuaries” [Sharkey and Stevenson 2001]. 
Altogether, this evidence excludes the possibility to eradicate infection through antiviral therapy 
alone [Maldarelli 2011; Siliciano and Green 2011]. In addition, even if accessible to anti-retroviral 
treatment, latently infected cells represent a safe and stable hideout for the virus, capable of 
refuelling virus replication. 
Recent studies have reported that IFN treatment can help suppressing initial viral transmission. HIV-
1 infected patients treated with pegylated-IFNfor 12 weeks were found immunologically stable 
after therapy withdrawal [Asmuth et al, 2010]. IFNα treatment drastically reduced the viral load at 
the beginning, and then followed by a little increase of HIV-1 viremia before treatment stop. The 
decrease of viremia has been linked to the increased expression of ISG, like MX2, in patients’ 
peripheral blood mononuclear cells (PBMCs) [Hubbard et al, 2012; Azzoni et al, 2013]. However, it 
is important to contextualize the IFN responsiveness according to the patient, since the extent of 
ISG upregulation is highly variable. Al together these reports suggest a potential application of IFN 
treatment to hit HIV-1 infected cellular reservoir as potential step towards HIV-1 cure [Barouch and 
Deeks, 2014] 
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The way in which HIV-1 exerts its pathogenicity is still a matter of discussion. Based on the reports 
collected so far, it is possible to assess that the infected cells die from the effects of infection alone, 
but their lifetime is somehow affected by the cytotoxic T cells response CD8+ (CTL), speciﬁcally when 
virus is being produced. Therefore, CD8+ mediated response may modulate infection without 
eliminating it. The chronic immune response activation might play a role in favour of viral 
replication, since the production of activated memory CD4+ T cells increases the number of available 
target cells leading to the immune system collapse [Coffin and Swanstrom, 2013].  
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1.5.3 Epidemiology and prevention 
AIDS represents the biggest public-health crisis of our time. Available antiretroviral treatment has 
reduced the morbidity and mortality of the disease, turning it into a chronic, manageable condition. 
Unfortunately, therapeutic approaches are not always easily available in the developing countries, 
where AIDS is highly prevalent. Indeed, sub-Saharian Africa remains the epicentre of the pandemic 
with the highest rates of new HIV-1 infections [Hayes and Weiss, 2006], accounting for 66% of the 
worldwide infections only in 2014 [UNAIDS, 2015]. The broad implementation of suitable 
infrastructures in these regions is therefore a scientific, economic and political imperative. 
Sexual route is still the main way of transmission [Hladik and McElrath, 2008; Cohen et al, 2011]. 
Another major way of HIV-1 transmission is the injecting drug use, particularly spread in Eastern 
Europe and central and Southeast Asia [UNAIDS 2013]. In the last 20 years, a burst on HIV-1 
infections has affected women [Quinn and Overbaugh, 2005] representing almost 48% of the 
infected individuals in the world, with the consequent implication of mother-to-child transmission 
[UNAIDS, 2014]. As a result, about 2.6 million of children below 15 years are currently affected by 
AIDS worldwide [UNAIDS, 2014]. HIV-1 prevalence may be increased by different factors within a 
population, like sexual practices and behaviour, the presence of other sex-linked diseases [Siegfried 
et al., 2003; Aral et al, 2005; Rottingen et al, 2005], migration waves [Bloom et al, 2002; Nunn et al, 
1995; Lurie et al, 2003], and finally drug and alcohol use [Buchbinder et al, 2005]. Remarkably, the 
co-infections with other sexually transmitted diseases in asymptomatic HIV-1 infected people can 
increase viraemia to levels observed in the acute phase of infection [Galvin et al, 2004]. Therefore, 
sexually transmitted diseases could enhance the rates of HIV-1 trasmission and at the same time 
may help to the identification of the pathological condition in asymptomatic patients [Cohen and 
Pilcher, 2005].  
The immediate treatment of recently infected people is an important preventing strategy to reduce 
HIV-1 transmission. Furthermore, encouraging safer sex practices through the use of condom has 
revealed a powerful preventing strategy [reviewed by Cates, 2005]. The increasing number of 
countries reporting declines in AIDS prevalence could be attributed to an efficient social awareness 
of preventive behavioural approaches like postponement of sexual debut, reduction in casual 
relationships and more consistent condom use in casual relationships [UNAIDS, 2006]. Prevention 
of mother-to-child transmission has been achieved by lowering intra-partum and breast feeding 
transmission [McIntyre, 2006; Newell, 2006; Magoni et al, 2005; Tuomala et al, 2002]. Other  
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preventing interventions in resource-constrained countries include male circumcision [Patteron et 
al, 2002; Szabo and Short, 2000] and chemoprophylactic treatment of other sexual transmitted 
infections like herpes simplex virus-2 (HSV-2), bacterial vaginosis, candidosis and trichomonas 
vaginalis [Corey et al, 2004; Schwebke, 2005].  
In the absence of a protective vaccine or a cure, prevention and availability of antiretroviral 
treatments are the best possibilities to reduce the HIV-1 pandemic. The constantly evolving HIV-1 
viral diversity makes the development of any preventive or therapeutic intervention very 
challenging [Korber et al, 2001]. Moreover, co-infections of different HIV-1 isolates may occur in the 
same indivual with the consequent implication of recombination events between the viral genomes 
[Thomson and Najera, 2005; Blackard et al, 2002], leading to the production of new drug resistant 
strains and to a faster clinical progression to AIDS [Gottlieb et al, 2004]. 
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1.5.4 Treatment 
Although a set of highly active antiretroviral therapies (HAART) can increase the AIDS patients’ life 
expectancies, they do not provide a definitive eradication of HIV yet, as consequence patients must 
take the drugs daily for life. In addition, they show some adverse side effects in terms of costs and 
toxicity [Schackman et al, 2006; Chen et al., 2006]. A wide range of aspects and principles needs to 
be considered for the production of an effective anti-HIV vaccine as well as a deep knowledge of 
HIV interaction with the immune system is required. Very powerful immunogens are necessary for 
cross-clade neutralizing antibodies production (NAbs) and an efficient T-cell response induction. In 
order to be eligible as potential HIV vaccine, the candidate molecules must provide a constant and 
long-term protection against future challenges during the clinical trials. In addition, safety and 
potential side effects are other important parameters that need to be considered. HIV structural 
[Asmuth et al, 2010; Sacha et al, 2007], regulatory [Bellino et al, 2009] and accessory proteins 
[Ayyavoo et al, 2010] are eligible as immunogenic molecules for vaccine development.  
Viral vectors [Draper and Heeney, 2010; Rerks-Ngarm et al, 2009], like adenovirus (Ad5) and 
modified vaccinia virus Ankara (MVA), and plasmid DNA vectors [Scheid et al., 2009] have been 
properly engineered to express HIV recombinant proteins as antigenic factors [reviewed by 
Schiavone et al., 2008] (Fig 16). The main limit of the employment of such vectors relies on the pre-
existance of antibodies against them inside the organism, leading to their rapid removal [reviewed 
by Chhatbar et al, 2011]. In the STEP trials, alternative human serotypes vectors with lower 
seroprevalence have shown a better advantage. In 2010 Kibuuka et al. reported a safer and more 
efficient multiclade DNA vaccine primed with a replication-defective rAd5 boost. Therefore, the 
combination of a DNA-based vector priming followed by an MVA boosting strategy induces a strong 
but temporary immune response. 
Virus-like particles (VLPs) (Fig 16) and liposome has been exploited as a safe delivery systems for 
immunogens like the envelope spikes in their native conformation [reviewed by Chhatbar et al, 
2011], as they do not contain the viral genome [Jennings and Bachmann, 2008]. The negative 
aspects about their employment consists in the possibile stimulation of antibodies against other 
membrane proteins and in the failure of exposing a functional trimeric Env [Crooks et al, 2007]. 
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Figure 16. Diagrammatic representation of safety and efficacy issues related to vaccine. From Drug Discovery Today 
16, 948-956 
 
Live attenuated or heat killed viruses (Fig 16) are considered highly efficient immunogenic factors 
for vaccines against HIV and SIV, but the possible generation of recombinant viruses poses a big 
safety issue [Reynolds et al, 2008]. In addition, once in the cells the protein expressed by live viral 
vectors have to compete with the exposed ones for antigen presentation [Harrington et al, 2002]. 
The isolation of broadly neutralizing antibodies (bNAbs) [Burton et al., 2005] from AIDS patients has 
led to a re-evaluation of an antibody-based approach for therapeutic purposes. The interaction of 
two somatic IgG variants VRC01 and VRC02 with CD4 binding region of gp120 mimics the interaction 
of CD4 and gp120 itself. Interestingly, VRC01, VRC02, VRC03 are able to neutralize 90% of circulating 
HIV-1 isolates [Wu et al.,2010]. Therefore, they are known as broadly neutralizing antibody and they 
are neither common nor of long duration [McElrath et al, 2010] and require time to be developed 
[Stamatatos et al, 2009; Haynes et al, 2010].  
In order to completely eradicate the disease, the latent CD4+ T cells reservoir has to be destroyed. 
One of the latest clinical studies has reported a smart approach to push the latent viruses out from 
the cell and leading to the elimination of the cell itself. The strategy is named “shock and kill” (Fig 
17). The histone deacetylase inhibitor Vorinostat, a therapeutic molecule for cancer treatment, has 
been tested for anti-latency activity. Purified resting memory CD4+ T cells from patients were 
exposed to gradually increasing doses of the molecule and at the end of the treatment they found 
a considerable increase of HIV RNA in the resting cells. A combined action of immune system and 
antiretroviral therapy could therefore lead to the complete elimination of HIV latent reservoir 
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[Archin et al, 2012]. This approach opens the way to novel strategies to straightaway attack and 
eradicate latent HIV infection.  
 
 
Figure 17 Shock and kill approach From Deeks, 2012. Nature 487, 439-440 
 
Recently, another approach aimed to directly target the pool of resting cells containing the virus 
reservoir has been proposed. It consists in the in vitro excision of the proviral DNA following the 
expression of a site-specific recombinase (Tre) within a lentiviral self-inactivating vector in HIV-1 
infected cells. Tre recombinase recognizes a specific 34 bp sequence inside the proviral LTR regions, 
leading to the excision of the proviral DNA from the infected cell genome [Sarkar et al, 2007]. The 
additional evidences in vivo systems supports the Tre-recombinase strategy as an eligible approach 
for therapeutic purposes [Hauber et al., 2013]. This kind of strategy could be used in combination 
to different antiviral approaches based on drugs interfering with viral life cycle, immunogenic 
molecules and antibodies. 
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1.6 NEF  
 
Nef is a 27-32 kDa accessory protein expressed only by primate lentiviruses (HIV-1, HIV-2 and SIV). 
It was firstly identified in 1985 as 3’ ORF, partially overlapping with the 3’ LTR in the HIV-1 genome 
[Ratener et al, 1985; Sanchez-Pescador et al, 1985]. After many initial controversial reports [Luciw 
et al., 1987; Ahmad and Venkatesan, 1988; Niederman et al., 1989; Hammes et al., 1989; Kim et al., 
1989] which contributed to its definition as Negative Factor, hence the currently Nef name, evidence 
of its actual positive role on infectivity in vivo finally came out. Studies on both SIVmac239 infected 
Rhesus macaques [Kestier et al., 1991] and HIV-1 infected patients [Deacon et al., 1995; Kirchhoff 
et al., 1995] supported the requirement of the Nef protein for viral replication and the timely 
development of immunodeficiency. Evidence in vitro of the Nef effect on HIV-1 replication in 
primary cell culture subsequently emerged [Terwilliger et al., 1991; de Ronde et al., 1992; 
Zazopoulos and Haseltine, 1993; Miller et al., 1994; Spina et al., 1994].  
Crystal and NMR structure studies reported Nef as a globular protein flanked by an N-terminal 
flexible arm and a C-terminal disordered loop [Lee et al., 1996; Arold et al., 1997; Grzesiek et al., 
1996 and 1997] (Figure 16). The myristoyl group at the N-terminus, followed by a cluster of basic 
aminoacidic residues [Bentham et al., 2006], targets Nef to the inner leaflet of the membrane [Wang 
et al, 2000; Zheng et al, 2001], and to perinuclear compartments [Kohleisen et al., 1992; Fujii et al., 
1996; Greenberg et al., 1997]. Although Nef does not show any enzymatic activity, it is able to take 
actively part to important host cell mechanisms. A di-leucine motif in the disordered C-terminal 
loop, together with a cluster of acidic residues in the disordered loop and in the core domain, 
mediate Nef interactions with a wide range of host factors involved in intracellular trafficking [Aiken 
et al., 1994; Piguet et al., 1999 and 2000], representing a crucial feature allowing its multi-
functionality. 
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Figure 18. A model of full-length Nef, anchored to the cellular membrane. From Arold and Baur, 2001, TRENDS in 
Biochemical Science 6-26 
 
Nef modulates expression of different cell surface molecules [Landi et al., 2011], like the CD4 
receptor [Garcia and Miller, 1991] and the major histocompatibility complex-I MHC-I [Schwatz et 
al., 1996], although with different mechanisms. CD4 receptor is internalized through clathrin-
mediated endocytosis [Aiken et al., 1994; Chowers et al., 1994; Rhee and Marsh, 1994; Schwatz et 
al., 1995a; Bresnahan et al., 1998; Craig et al., 1998; Piguet et al., 1998 and 1999; Janvier et al, 2001.; 
Faure et al., 2004] in order to prevent a toxic super-infection of the target cells [Benson et al, 1993; 
Little et al, 1994] and to avoid its interaction with envelope glycoproteins. This way, Nef promotes 
viral dissemination [Benson et al., 1993; Little et al., 1994] and envelope glycoproteins incorporation 
into the viral membrane [Lama et al., 1999; Cortes et al., 2002; Arganaraz et al., 2003; Lundquisit et 
al., 2004; Schiavoni et al., 2004]. The mechanism by which Nef performs the downmodulation of 
MHC-I is still debated, nevertheless it seems to be AP2/clathrin independent and to involve PAC 
(phosphofurin acid cluster sorting) proteins [Piguet et al., 2000; Blagoveshchenskaya et al., 2002; 
Williams et al., 2002, 2005; Larsen et al., 2004; Roeth et al., 2004; Lubben et al., 2007; Noviello et 
al., 2008; Dikeakos et al., 2012]. Nef is also able to impair MHC-II functions [Mu et al., 2003] and to 
induce FasL expression, leading to the apoptosis of bystander cytotoxic cells [Xu et al, 1997; 1999]. 
Altogether, these mechanisms represent a Nef strategic system to protect infected cells by the 
cytotoxic action of immune T cells mediated response [Collins et al., 1998]. Remarkably, Necf 
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modulation of the cell surface molecules described so far is conserved among all primate 
lentiviruses (HIV-1, HIV-2 and SIV) [Schindler et al., 2003] and maintained throughout disease 
progression [Carl et al., 2001]. In the end, Nef impairs T-cell receptor (TCR) activity through CD28 
down regulation in HIV [Bell et al., 2001; Swigut et al., 2001], and TCR/CD3 complex down 
modulation by SIV Nef alleles [Schindler et al., 2006; Schaefer et al., 2000; Munch et al., 2002]. 
Nef plays an important role in modulating cell signaling. Its structural features include the proline-
rich motif [Saksela et al., 1995], an amphipatic α-helix in the N-terminal arm [Baur et al., 1994] and 
an hydrophobic stretch within the C-loop [Agopian et al., 2006], implicated in interactions with 
different kinds of cellular kinases [Saksela et al., 1995; Sawai et al., 1994, 1996; Khan et al., 1998; 
Renkema et al., 1999; Agopian et al., 2006] and adaptors [Fackler et al., 1999; Rauch et al., 2007] 
involved in T-cells activation. This net of interactions affects the T-cells transcriptional regulation, 
modulating their activation status and creating a suitable environment for viral replication.  
Taken together these reports suggest that Nef works as an adaptor between intravescicular 
trafficking and signaling pathways thanks to its ability to bind a wide range of interactors inside the 
host cells through its multiple binding motifs.  By mediating the interaction between cellular protein 
and factors from the endocyotis machinery, Nef is able to modulate their intracellular trafficking. 
Apart from CD4 downmodulation, Nef is able to re-route peripheral membrane protein like Src 
family kinases too. Nef involvement in cytoskeletal remodelling and cell motility creates a favorable 
environment for cell to cell virus transfer. Moreover, Nef induces the secretion of chemockines (like 
MIP1- ) inducing the migration of non infected cells towards the infected ones [reviewed by 
Laguette et al, 2010; Fackler et al, 2007; Geyer et al, 2001; Roeth and Collins, 2006]; Muratori et al, 
2009]. Nef exists also as  soluble form, as secreted protein by infected cells, affecting the viability of 
bystander T cells and inducing B cells dysfunctions [Lenassi et al, 2009; Moir and Fauci, 2009] 
Evidence in vivo strongly confirmed Nef requirement for viral replication [Kestier et al, 1991; Deacon 
et al, 1995; Kirchhoff et al, 1995], while controversial reports about its role in vitro have left the 
question open. A strong Nef effect on viral replication was reported in macrophages and in 
unstimulated T-cells in vitro [Miller et al., 1994; Spina et al., 1994]. Conversely, in activated primary 
human T-cells cultures only a marginal Nef effect was reported on viral replication in both cell-free 
viruses and cell-associated viruses mediating cell-to-cell spreading infection [Haller et al., 2011; 
Malbec et al, 2013]. 
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1.6.1 Nef role in infectivity 
The effect of Nef on virion infectivity was confirmed by several research groups in different contexts 
[Chowers et al., 1994; Aiken and Trono 1995; Goldsmith et al., 1995; Miller et al., 1994; Tokunaga 
et al., 1998; Khan et al., 2001; Tobiume et al., 2001; Papkalla et al., 2002]. The mechanism behind 
the Nef requirement for HIV-1 infectivity has remained poorly understood since the first evidence 
reported by Chowers and colleagues in 1994. None of the Nef functions described so far seems to 
correlate with the still elusive role of Nef in the infectivity enhancement. Firstly, Nef is able to 
increase infectivity when HIV is produced in CD4 negative cells [Chowers et al., 1995; Goldsmith et 
al.,1995] and in the context of virions pseudotyped with envelopes not interacting with CD4 [Miller 
et al, 1995; Pizzato et al., 2008], suggesting that the infectivity increase is not a consequence of the 
effect of Nef on the surface level of CD4 in producer cells. Moreover, Nef increases cell-free virus 
infectivity also in non-T-cell systems [Miller et al., 1994], indicating that the sought Nef activity does 
not depend on the activation status of T-cells. Despite having a clear effect on infectivity, Nef only 
marginally affects the viral replication in vitro [Haller et al., 2011]. Interestingly, the molecular 
features of Nef important for its involvement in vesicular trafficking, seem to be fundamental for its 
activity on infectivity, providing an indication of a functional link between the two activities. 
Importantly, Nef activity on infectivity is phylogenetically conserved among diverse HIV and SIV 
isolates [Munch et al., 2007] and is maintained throughout the disease progression [Carl et al., 
2001].  
The first insight about the mechanism behind Nef effect on infectivity came by demonstrating that 
the the viral protein requires to be expressed in virus producer cells rather than in target cells [Aiken 
and Trono, 1995]. Indeed, the infectivity impairment shown by Nef-depleted viruses could be 
rescued by expressing Nef in trans in producer cells rather than target cells [Aiken and Trono, 1995]. 
Further studies have proved that the extent by which Nef affects HIV-1 infectivity is strictly 
dependent on the producer cell line [Pizzato et al., 2010]. However, Nef seems to be particularly 
required when the viruses are produced by lymphoid cell lines [Pizzato et al., 2010]. Interestingly, 
impairments of Nef interaction with clathrin-mediated endocytosis factors, like dynamin and AP2, 
strongly affect virions infectivity [Chowers et al., 1994; Pizzato et al., 2007], suggesting that 
intracellular trafficking in virus producing cells may play a crucial role in the infectivity modulation. 
Nef association with membrane rafts [Wang et al., 2000] allows its incorporation into viral particles, 
where it is found both in association with viral envelope and partially in a soluble form due the 
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cleavage by viral proteases during the maturation step [Pandori et al., 1996; Welker et al., 1996, 
1998; Bukovsky et al., 1997]. Thus, it was proposed that Nef takes part to the formation of the 
budding scaffold in the producer cells and due to its ability to bind both reverse transcriptase and 
integrase enzymes [Ciuffi et al., 2004] could affects early steps of infection in the target cells. 
However, site-direct mutagenesis experiments affecting Nef incorporation and maturation into 
virions confirmed no correlation with infectivity enhancement [Chen et al., 1998; Miller et al., 1997; 
Welker et al., 1998]. Additionally, Nef can be also incorporated into MLV particles without affecting 
their infectivity [Bukovsky et al., 1997]. Taken together, all these reports collectively exclude the 
requirement of Nef incorporation into viral particles to enhance the infectivity, suggesting that the 
progeny viruses acquire a modification in the producer cells that enhances their infectious potential. 
Two issues have therefore remained unsolved: the type of modification acquired by the viral 
particles affecting the infectivity and the step of the virus biogenesis affected by Nef (Figure 19). 
Two reports have tracked the Nef effect on infectivity to the biogenesis of the viral particles, 
demonstrating that the infectivity enhancement requires Nef association with the virus assembly 
complex [Qi and Aiken, 2008; Laguette et al., 2009]. Thus, the virions seem to acquire a Nef-
dependent modification during the late events of lifecycle.   
 
 
Figure 19. Localization of Nef activity on virus infectivity. Nef effect on infectivity is acquired in the producer cells at 
the level of viral biogenesis (1) and it is visible during the early steps of infection at the level of target cells (2). From 
Basmaciogullari and Pizzato (2014), Frontiers in Microbiology, 5-232.  
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Altogether, available data support the hypothesis that the Nef-mediated modification acquired by 
the nascent virus particle could consist of a preferential incorporation or exclusion of one or more 
cellular factors. Nef was shown to affect the lipid composition of viral membrane [Brugger et al, 
2007; Zheng et al, 2003 and 2001]. In particular, Nef was observed to increase cholesterol synthesis 
and transport to lipid rafts enhancing its incorporation into the viral membrane. As consequence, 
Nef defective virions show a lower content in cholesterol compared to wild type (Figure 16) [Zheng 
et al, 2003]. However, this result was not confirmed by another study [Brugger et al., 2007].  
Although other differences have been traced by proteomic analysis in WT and Nef-defective virions 
[Bregnard et al, 2013], none was able to fully explain Nef requirement for infectivity. Overall, these 
reported modifications in the viral particles conferred by Nef, represent a proof of its effect on virus 
biogenesis. 
 
Figure 20. A model for the effects of Nef on viral infectivity. Nef is expressed as an oligomer abundantly before viral 
structural proteins.It activates cellular signaling cascades and causes cytoskeletal rearrangements (step 1). These lead 
to increased transcription of at least one cholesterogenic enzyme, CYP51 (step 2). Increased CYP51 activity (blue circles) 
increases synthesis of cholesterol (red circles) in the endoplasmic reticulum (step 3). The model shows the transport of 
Nef in viral assembly intermediates (step 4) to lipid rafts (step 5). Nef and newly synthesized cholesterol are 
incorporated into DRM and virions (step 6). More infectious viral particles are released into extracellular space (step 7). 
Nef is also cleaved by the viral protease in virions (step 7). From Zheng et al., 2003, PNAS 100-14. 
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At the level of target cells, the Nef effect on infectivity results in an optimization of post-entry events 
required to efficiently synthesize the viral DNA [Aiken and Trono, 1995; Chowers et al., 1995; 
Schwartz et al, 1995]. Indeed, viral particles containing Nef yeald a higher amount of early reverse 
transcription products than Nef depleted virions [Aiken and Trono, 1995; Chowers et al., 1995; 
Schwartz et al, 1995]. Therefore, Nef ability to enhance infectivity might be exerted at the fusion 
step between the virus and cell membrane and/or at an immediately subsequent level [Schaeffer et 
al., 2001; Campbell et al., 2004]. It was suggested that when viral entry takes place via endocytosis, 
Nef becomes dispensable. However, it was more recently established that Nef responsiveness is 
strictly determined by the nature of the envelope glycoprotein [Lai et al., 2011; Usami and 
Göttlinger, 2013] and is not dependent on the viral entry route [Miyauchi et al., 2009; van 
Wilgenburg et al, 2014]. With reference to fusion, controversial reports have been collected so far. 
Nef enhancement of cytoplasmic delivery of virions together with stimulation of intravirion fusion 
have been proposed [Schaeffer et al., 2001; Zhou and Aiken, 2001], in contrast with other reports 
showing no Nef effect of the fusion step [Miller et al., 1995; Tobiume et al., 2003; Cavrois et al., 
2004]. Using the same assay as the previous studies, another report revealed a mild effect of Nef in 
enhancing virus fusion with the cells [Delay et al., 2004]. Altogether, these contradictory reports are 
the result of a lack of a robust and sensitive fusion assay. 
In 2010 a protein with a Nef-like activity was discovered in a gammaretrovirus (MLV) [Pizzato, 2010]. 
Most gammaretroviruses express and accessory protein whose translation from unspliced RNA 
starts from an alternative CUG initiation codon, localized upstream and in frame with the Gag 
protein coding sequence[Edwards and Fan, 1979; Evans et al., 1977; Neil et al., 1980; Schultz et al., 
1979; Prats et al., 1989]. As a result, gammaretroviruses express a leader sequence at the N-
terminus of the conventional Gag, and the resulting protein, termed glycoGag, is targeted to the cell 
membrane. This protein shows a tipe II transmembrane topology and it is glycosylated. Glycogag 
from MLV seems to be involved in viral replication in vivo with a still undefinied mechanism 
[Schwartzberg et al., 1983; Goff and Lobel, 1987; Chun and Fan, 1994; Fan et al., 1983; Corbin et al., 
1994; Fujksawa et al., 1998; Munk et al., 2003]. Ectopic expression of Glycogag in cells producing 
Nef-depleted HIV rescues virus infectivity [Pizzato, 2010] despite sharing no sequence homology 
with Nef. The requirement of glycogag for infectivity is Env-dependent and determined by the virus 
producer cells [Pizzato, 2010; Usami and Göttlinger, 2010]. Nef and Glycogag colocalize [Pizzato, 
2010] and both have been reported to facilitate virus release through lipoid rafts [Zheng et al., 2000; 
Nitta et al., 2010]. The defect in infectivity acquired by MLV and HIV in the absence of Glycogag and 
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Nef, is reflected in an equally early step of the infectious process [Aiken and Trono, 1995; Chowers 
et al., 1995; Schwartz et al, 1995; Pizzato, 2010]. Altogether, these indications suggest that Nef and 
glycoGag are te result of convergent evolution. 
Viral auxiliary proteins play an important role in infectivity of lentiviruses, due to their involvement 
in the neutralization of the so-called cellular “restriction factors”. The host cells are provided with 
intrinsic mechanisms to protect themselves from viral infections. The ability to counteract restrictive 
cellular activities have been identified for Vif, VpU and Vpx. We have been hypothesizing that the 
Nef activity on infectivity could also be explained by its ability to counteract a restriction factor. My 
PhD research project has provided important insights about cellular and molecular basis of Nef 
requirement for HIV-1 infectivity, which will be discussed further in this dissertation. 
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1.7 Intrinsic antiviral immunity: HIV restriction factors 
 
Vertebrates have evolved a versatile and complex protein-based antiviral immunity, shaped by the 
constant exposure to many pathogens. They express a wide range of pattern-recognition receptors 
(PRRs), recognizing molecular patterns of viruses and other pathogens and triggering antiviral 
interferon and proinflammatory response afterwards [Iwasaki and Medzhitov, 2010]. Their 
inhibition of viral infection relies on the activation of signaling cascades resulting in the 
transcriptional activation of antiviral factors. Proteins detecting viral nucleic acids inside the host 
cell like Toll-like receptors (TLRs), RIG-I (cytosolic retinoic acid inducible gene I) like receptors (RLRs), 
Node-like receptors (NLRs) and C-type lectin receptors are some example of mammalian PPRs.  
An early line of defense against the viral threat is represented by the intrinsic antiviral immunity, 
which is considered part of innate immunity and is conferred by restrictive cellular activities. Overall, 
these inhibitory elements are known as restriction factors, due to their antiviral action [Bieniasz, 
2004; Goff, 2004]. Despite the absence of an unambiguous definition of these antiviral proteins 
[Doyle et al., 2015], they share some specific features. The restriction factors are able to interact 
with specific viral antagonists blocking the viral replication straightaway, often before the 
stimulation of interferon response. Their expression is generally constitutive, allowing their 
immediate action during viral invasion, but it can be upregulated by interferon upon the detection 
of viral infection. Remarkably, they are able to exert the antiviral activity as single genes, without 
the involvement of any cellular cofactors. A positive selective pressure drives the rapid 
diversification of both restriction factors and viral antagonists throughout the evolution. The 
exposure of a host restriction factor to iterative rounds of viral conflicts may lead to the selection 
of variations across the restriction factor sequence that make it resistant to the viral counteraction. 
Over the evolution, this result in an overabundance of amino acid non-synonymous substitutions 
(dN) in correspondence of the domains mainly involved in the virus restriction. This positive 
selection signature is shared by most of restriction factors identified so far [reviewed by Duggal and 
Emerman, 2010]. Since the amino acid sequence of each restriction factors has been finely tuned 
by many previous host-pathogen conflicts, the host antiviral elements may define the viral-host 
range, mediating a powerful specie-specific suppression and limiting cross-species transmissions. 
For instance, HIV-1 has adapted to overcome the restriction in its natural target cells (human cells) 
but it is sensitive to the restrictive activities present in other hosts. Therefore, the presence of 
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restriction factors determines the susceptibility of the cells to the viral invasion. The investigation 
of the differential susceptibility displayed by diverse target cells, combined with comparative 
transcriptomic studies has led to the discovery of important HIV-1 antiviral factors such as 
APOBEC3G [Sheehy et al., 2002], TRIM5Stremlau et al., 2004BST-2 [Neil et al., 2008; Van 
Damme et al., 2008] and SAMHD1 [Laguette et al., 2011; Hrecka et al., 2011]. 
 
1.7.1 APOBEC3G 
APOBEC3G is one of the first HIV-1 restriction factors identified. The approach followed was based 
on the investigation of the variable responsiveness to the 23 kDa accessory protein Vif (Virion 
Infectivity Factor) observed in different virus-producing cell lines [Sheehy et al., 2002]. ABOBEC3G 
is a host protein belonging to a family of polynucleotide cytidine deaminase expressed in several 
human tissues and in particular in hematopoietic cells [Koning et al., 2009; Refsland et al., 2010]. In 
absence of Vif, APOBEC3G is incorporated into the HIV-1 virions through its interaction with the 
nucleocapsid (NC) region of Gag [Bogerd and Cullen, 2008]. Its restrictive activity is exerted during 
the viral reverse-transcription step (Figure 19). Thanks to its association with the viral reverse 
transcriptase complex (RTC), APOBEC3G mediates the editing of cytidine residues to uridines during 
the first DNA strand synthesis [Harris et al., 2003; Mangeat et al., 2003; Zhang et al., 2003; Yu et al., 
2004] in a sequence specific manner [Harris et al., 2003; Yu et al, 2004]. This kind of modification 
results in guanosine-to-adenosine hypermutation of the HIV DNA genome, often determining the 
formation of premature stop codons in the viral DNA sequence. Interestingly, the presence of 
guanosine-to-adenosine mutations has been detected in the viral DNA isolated from AIDS patients 
[Vartanian et al., 1991], although the modulation of APOBEC proteins in the context of natural HIV-
1 infection is not well defined yet. Evidence about the further inhibiting activity of the host factor in 
the reverse transcription and integration steps [Iwatani et al., 2007; Bishop et al., 2008; Mbisa et 
al., 2007] still lacks of a mechanistic explanation. HIV-1 accessory protein Vif counteracts APOBEC3G 
restrictive activity by promoting its polyubiquitylation and subsequent proteasomal degradation in 
the producer cells, in order to prevent its incorporation into nascent viral particles [Sheehy et al., 
2003; Marin et al., 2003; Stopak et al., 2003; Yu et al., 2003]. Remarkably, the polyubiquitylation 
step defines a critical and direct interaction between Vif and APOBEC3G which poses a barrier to 
inter-species transmission. Mutation in amino acidic residues localized in APOBEC3G domains 
involved in the recognition by Vif, modulate the sensitivity of the protein to different Vif alleles from 
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different species. For instance, APOBEC3G from African green monkey is recognized by SIVAGM Vif 
but is resistant to HIV-1 Vif counteraction [Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer 
et al., 2004]. Therefore, the interaction between Vif and APOBEC3G is specie-specific. In addition to 
APOBEC3G, primates encode six more APOBEC genes, of which APOBEC3D, APOBEC3F and 
APOBEC3H show restrictive activity against HIV-1 [Hultquisit, 2011]; although their restrictive 
activity is less powerful than the one exerted by APOBEC3G [Holmes et al., 2007; Miyagi et al., 2010]. 
This difference in the magnitude of restriction might be reflected by their lower expression 
compared to APOBEC3G [Koning et al., 2009; Refsalnd et al., 2010]. All APOBEC proteins have 
diversified under strong positive selection during the evolution of primates [Sawyer et al., 2004] and 
their expression is induced by type I IFNs [Koning et al., 2009; Refsalnd et al., 2010]. This family of 
proteins display all the features shared by HIV-1 restriction factors.  
 
1.7.2 TRIM5 and TRIMCYp 
TRIM5α is a cytoplasmic protein able to bind retroviral capsid [Stremlau et al., 2006]. It belongs to 
the family of “tripartite motif (TRIM)-containing proteins, whose members share the same domain 
organization [Nisole et al., 2005]. Its restrictive activity has been identified expressing a library of 
cDNA from rhesus macaques in human cells [Stremlau et al., 2004].The bock exerted by TRIM5α 
might be tracked back to the uncoating step (Figure 19) [Stremlau et al., 2006] despite its restriction 
mechanism is not well defined yet. The capsid binding domain, known as PRYSPRY or B30.2 domain, 
is localized at the C-terminus of the protein and it is important for TRIM5α restrictive activity. Being 
directly involved in the interaction with the viral antagonist, PRYSPRY domain shows a high rate of 
non-synonymous mutations accumulated throughout the evolution [Sawyer et al., 2005; Song et al., 
2005; Johnson and Sawyer, 2009]. This fast accumulation of non-synonymous substitutions is a 
hallmark of a positive selective pressure, as result of multiple exposures to retroviral threats over 
the evolution. The capsid binding domain determines the specie tropism of retroviruses. As 
consequence of virus-host adaptation, a TRIM5α protein found in a host species usually inhibits 
retroviruses infecting other target species [reviewed by Malim and Bieniasz, 2012]. For instance, 
HIV-1 is resistant to human TRIM5 whereas N-MLV and EIAV are inhibited [Hatziioannou et al., 2004; 
Keckesova et al., 2004, Perron et al., 2004; Yu et al., 2004]. TRIM5α is therefore considered an 
example of cross-species barrier mediated by a restriction factor [Hatziioannou et al., 2006].  
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On the other hand, Cyclophillin A (CypA) is a host factor that helps HIV-1 to evade TRIM5 α 
restriction through its binding to lentiviral capsid [Berthoux et al., 2005; Keckesova et al., 2006; 
Stremlau et al., 2006]. A chimeric gene TRIMCyp, produced by the fusion of CypA cDNA with TRIM5 
locus, is naturally generated in owl monkeys and in some macaques as result of retrotrasposition 
events [Sayah et al., 2004; Liao et al., 2007]. The chimeric protein produced contains the CypA 
capsid-binding domain replacing the PRYSPRY domain of TRIM5α, resulting in a powerful lentiviral 
inhibitor [reviewed by Malim and Bieniasz, 2012]. A model proposed for both TRIM5α and TRIMCyp 
mediated restriction arose from the evidence of an accelerated capsid fragmentation after the 
binding of TRIM5α or TRIMCyp [Stremlau et al., 2006], implying the consequent RTC disruption and 
the block of reverse transcription. However, in addition to capsid binding, only the TRIM5α 
multimerization activity seems to be necessary for viral inhibition. Conversely, proteasome activity, 
accelerated capsid fragmentation and inhibition of reverse transcription do not seem to be  
absolutely required [reviewed by Malim and Bieniasz, 2012]. Mutations in viral capsid represent the 
strategy adopted by the viruses to evade the TRIM5α and TRIMCyp restrictions. Interestingly, apart 
from antiviral restrictive activity, TRIM5α has a more general role in antiviral signalling. It may act 
as pattern recognition receptor recognizing the capsid of many retroviruses (like MLV, HIV and SIV) 
and thus triggering an antiviral immune response [Tareen et al., 2011; Pertel et al., 2011] 
 
1.7.3 Tetherin 
Tetherin, known also as BST-2 or CD317, is an IFN induced membrane protein able to block the 
virions release from an infected cell [Neil et al., 2008; Van Damme et al., 2008]. The viral particle are 
trapped on the cell surface from which they are subsequently internalized into endosome [Neil et 
al., 2006]. Thanks to its particular structure, Tetherin may act as a bridge between the virus and the 
infected cell. It is actually provided of a transmembrane anchor at the N-terminus by which it 
infiltrates the virion envelope, and a lipid anchor at the C-terminal region which remains in the 
plasma membrane [Kupzig et al., 2003]. As consequence, it can restrict enveloped viruses belonging 
to diferent virus families since no specific recognition is required for its function [Le Tortorec et al., 
2011]. HIV-1 counteracts Tetherin action through its accessory protein Vpu (Figure 19) [Neil et al., 
2008; Van Damme et al., 2008], while SIVs use Nef protein [Jia e al., 2009; Zhang et al., 2009] and in 
some other primate  lentiviruses Env proteins may be also employed as tetherin antagonists [Gupta 
et al., 2009; Le Tortorec and Neil, 2009]. However, the counteraction mechanisms of Tetherin 
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mediated by the different antagonists in primate lentiviruses are still needs to be clarified. The lack 
of conservation in the viral antagonism of Tetherin between different primate lentiviruses is the 
result of past cross species infections that gave rise to the present HIV-1 and HIV-2. The instauration 
of zoonosis between SIVsm and SIVcpz and a different host (humans) have induced the virus to 
evolve a way to counteract human Tetherin, which is resistant to SIV Nef. Therefore, the relatively 
“recent” HIV-1 and HIV-2 have faced the need to develop a human Tetherin antagonistic activity 
played by Vpu and Env proteins respectively.   
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1.8 Intrinsic antiviral immunity: HIV resistance factors  
The features just described are not shared by all the antiviral factors identified so far. A new category 
of antiviral proteins without any identified viral antagonism has been recently defined as “resistance 
factors” [Doyle et al., 2015]. They are all interferon stimulated cellular activities causing a post-entry 
block of HIV-1 [Goujon and Malim, 2010; Cheney and McKnight, 2010]. 
Myxovirus resistance 2 (MX2) was one of the first resistance factors to be discovered as a powerful 
HIV-1 nuclear import and integration inhibitor induced by IFN. It is a Dynamin-like GTPase with both 
nuclear and cytoplasmic localization able to block the nuclear entrance and the integration of 
different HIV-1 strains. Although the mechanism of its antiviral activity is still poorly understood, 
MX2 is less powerful against SIVs strains, while it does not restrict other retroviruses like MLV. This 
evidence might suggest a possible mechanism linked to CA protein binding [Goujon et al, 2013; Kane 
et al, 2013; Melen et al, 1996; Goujon et al, 2014; Fricke et al, 2014; Fribourgh et al, 2014].  
A set of interferon induced transmembrane protein (IFTM1, 2 and 3) are expressed on cell 
membranes and get incorporated into viral particles. Being expressed on viral particles and target 
cells surfaces, they affect the entry step by disturbing the fusion between the virions with the 
membranes of target cells [Compton et al, 2014; Tartour et al, 2014; Lu et al, 2011]. 
Schlafen 11 (SLFN11) is an RNA binding protein blocking the translation of HIV-1 proteins, due to 
the different codon usage of HIV-1 transcripts. However, SLFN1 mechanism of action still remains 
elusive [Li et al, 2012]. 
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A summarizing representation of the host restriction mechanisms and the viral antagonism is 
described is reported in Figure 21. 
 
 
 
Figure 21. Host restriction and viral antagonism mechanisms. From Doyle et al., 2015, Nature Reviews Microbiology 13, 403–413 
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Genome wide screening approaches may represent useful tools for the discovery of new antiviral 
factors in the context of other viruses. The further investigation of the molecular mechanisms 
behind the antiviral factors action and their viral antagonism counteraction represents the current 
challenge. The insights gained by these studies will be employed for the development of future 
antiviral therapies and will broaden the knowledge of virus and host cell biology as well. 
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1.9 Aims 
 
The aim of this research project is to understand the mechanism by which Nef enhances HIV-1 
infectivity through the following objectives: 
 Studying the character of the Nef requirement for HIV-1 infectivity. 
Since Nef requirement for HIV-1 infectivity is reported to be highly dependent on the virions 
producer cell type [Aiken and Trono, 1995; Pizzato, 2010], several human cell lines of different 
histological origin have been used as HIV-1 producing cells in order to quantify the extent to 
which Nef is required to enhance virion infectivity. Due to the high variability of the requirement 
of the lentiviral accessory protein, I have tried to investigate whether Nef increases HIV-1 
infectivity by counteracting a cellular inhibitor or by promoting a cellular activity. To this 
purpose, I have produced Nef-positive and Nef-negative HIV-1 virions from heterokaryons 
derived from the fusion of two different cell lines with opposite Nef responsiveness. The high 
Nef-dependence of HIV-1 produced by heterokaryons has pointed put the presence of a cellular 
inhibitor mainly expressed in highly Nef responsive cell lines, which makes Nef activity necessary 
for its counteraction. 
 
 Identifying the cellular factor responsible for such requirement. 
Gene expression profiles of cell lines with marked difference in Nef responsiveness have been 
analysed and compared to identify differentially expressed genes, which correlate with Nef 
responsiveness. Based on the correlation analysis, SERINC5 emerged as the gene whose 
expression correlated best with the requirement of Nef for HIV-1 infectivity.  A functional study 
consisting in gene silencing (candidate gene knockout) and ectopic expression of the identified 
factor in virus producer cells with different Nef responsiveness has validated its involvement in 
HIV-1 infectivity enhancement. An extension of this kind of study to the other 4 genes belonging 
to the human SERINC family [Inuzuka et al, 2005] has revealed SERINC3 as another HIV-1 
inhibitor although less powerful than SERINC5. 
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 Identifying the pathway employed by Nef to enhance HIV-1 infectivity. 
According to what is reported in literature, Nef requires to be myristoylated and to interact with 
clathrin-mediated endocytosis machinery to enhance HIV-1infectivity [Craig et al., 1998; Pizzato 
et al., 1997]. Using gene-silencing approach (AP2 knockdown) together with a screening of a 
panel of Nef mutants impaired in different functions, I have found that the cellular pathway 
exploited by Nef to counteract SERINC5 is the clathrin-mediated endocytosis. Nef mutants 
impaired in the interaction with molecular partners from the endocytosis machinery as well as 
those affecting its membrane-anchored localization (myristoylation) are not able to counteract 
SERINC5 inhibitory activity. Immunostaining techniques have been used to show the differential 
localization of SERINC5 in presence of Nef. Nef-mediated internalization of SERINC5 is perfectly 
in agreement with the data supporting the involvement of clathrin-mediated endocytosis 
pathway, providing important insights about Nef molecular mechanism. Western blotting 
analyses have been used to check the amount of SERINC5 that gets incorporated into viral 
particles as well as the level of expression of the protein in virus producer cells. 
 
 Identifying the step of the HIV-1 life cycle where Nef protein is required 
Previous reports showed that in the absence of Nef protein the infection process is blocked at 
an early stage of the HIV-1 life cycle [Aiken and Trono, 1995]. Fully or almost completely reverse 
transcribed HIV-1 genomes can be measured by qPCR using a couple of primers matching on the 
upstream LTR and on the region downstream the primer binding site. The viral DNA detected is 
a late product of reverse transcription since it is produced upon the second template switch 
step. This kind of assay is known as Late RT assay [Butler et al, 2001] and it has been used to 
show how Nef defective HIV-1 virions fail to accumulate products of reverse transcription in 
target cells. Due to a lack of a sensitive and reliable fusion assay, controversial evidence about 
the eventual role of Nef in the fusion between the virions and the target cells are reported in 
literature [Campbell et al, 2004; Schaeffer et al, 2001; Zhou and Aiken, 2001; Tobiume et al, 
2003; Cavrois et al, 2004; Day et al, 2004]. Thanks to the development of a novel a more sensitive 
fusion assay by my collaborators [Rosa et al, 2015], I was able to collect some indications about 
the defect acquired by the virus in presence of SERINC5 in the delivery of its core into the 
cytoplasm. 
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2. MATERIALS AND METHODS 
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2.1 Nef counteracts a retrovirus inhibitor 
 
2.1.1 Cells and transfection methods 
The cells, the transfection methods and the infectivity assay are described in Methods section from 
Rosa et al, 2015. 
 
2.1.2 Transfection Plasmids 
Plasmids used to transiently express RNAseH enzyme in HT1080 and HEK293T cells are reported in 
table2 
 
Table 2. Transfection plasmids 
Name Gene Reference 
pcDNA RNaseH A subunit RNaseH A A kind gift from Dr C. Reinhard 
pcDNA RNaseH B subunit RNaseH B A kind gift from Dr C. Reinhard 
pcDNA RNaseH C subunit RNaseH C A kind gift from Dr C. Reinhard 
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2.2 SERINC5 does not evolve under positive selection pressure 
 
The human SERINC5 gene produces four different splicing isoforms, whose protein products differ 
for about 40 amino acid residues clustered at the C-terminus of the protein (Figure 22). The positive 
selection analysis was performed on the human SERINC5 splicing isoform number 3 (QU86VE9-3), 
which is the one used to perform all my experiments.  
 
 
  
Figure 22. SERINC5 human splicing isoforms. Alignment of human SERINC5 splicing isoforms shows differences at 
the C-terminus of the protein produced. 
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Firstly, a virtual transcript for each primate sequence analyzed has been created, by aligning each 
SERINC5 ortholog sequence with the human SERINC5 gene sequence using blastn (basic logical 
alignment search tool nuceotide) and splicing together the exons identified. In order to understand 
the variation in the human SERINC5 exons, its coding sequence has been compared with those 
virtually produced in the other species through a multiple alignment 
(MUltiple Sequence Comparison by Log- Expectation), in which the human reading frame has been 
kept as reference. The gaps inserted by the alignment, due to the nucleotides removed throughout 
the evolution, were removed in the analysis in order to maintain the reading frame. To construct a 
phylogeny based on the alignment produced, the evolution model is a necessary parameter. 
Therefore, a statistical selection of best-fit models of the nucleotide substitutions detected in the 
alignment produced has been performed using JmodelTest2. This tool provides a ranking of possible 
evolution models fitting with the alignment that is used as input. The parameters of the best ranked 
model, according to the statistical score, were  used to construct a phylogenetic tree based on the 
alignment of the coding sequences of the species analyzed (MrBayes software). The phylogeny 
constructed was in good agreement with the accepted primate phylogeny, indicating the fidelity of 
the alignment. Maximum likelihood analysis was performed using CODEML, part of the PAML 3.14 
software package [Yang, 1997]. Likelihood Ratio tests [Yang, 1998] were used to verify if a positive 
selection model fits with the evolution model of the input sequences. The LRT was used to compare 
the likelihood of different models of evolution (M1 vs M2 and M7 vs M8). A resulting p-value lower 
than the chosen threshold indicates that the sequence can be under the effect of positive selection. 
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2.3 Optimization of a purification protocol for SERINC5 protein 
 
2.3.1 Cell culture methods 
 
HEK293T cell were grow in DMEM supplemented with 10% FBS at 37°C with 5% CO2. 
2.3.2 Construction design for SERINC5 recombinant protein 
Human SERINC5 cDNA expressing a recombinant protein fused with a 3C protease recognition site 
followed by a FLAG and STREP tags in tandem  at the C-terminus was created by PCR and cloned in 
a pcDNA3.1 expression vector (Life Technologies) using primers MP1082, MP1083 and MP1084 
(table 3). 
Another version of human SERINC5 cDNA fused at the C-terminus to a 3C protease recognition site 
followed by two STREP tags in tandem has been cloned in a pESG-IBA 103 vector (Stargate) using 
primers PC1001 and PC1002 (table 3).   
 
Table 3.  List of primers to produce recombinant SERINC5 
PRIMER SEQUENCE 5’->3’ COMMENT 
MP1082 GCGCCCAAGGTCACCCGGGCCCTGAAACAGCACTTCCAGTCCGGACACAGAGAACTC SERINC5-3C-
STREP-FLAG in 
pcDNA vector 
MP1083 TTTATAATCTTTTTCAAACTGCGGATGGCTCCACGCGCGCCCAAGGTCACCCGG SERINC5-3C-
STREP-FLAG in 
pcDNA vector 
MP1084 GTGGTGGAATTCAGTTATTTATCATCATCATCTTTATAATCTTTTTCAAACTGC SERINC5-3C-
STREP-FLAG in 
pcDNA vector 
PC1001 TCATGTATTCCATTGCCACTGGAGG SERINC5-3C- 
2XSTREP in pESG 
vector 
PC1002 CTTATTTCTCGAACTGCGGGTGGCTCCACG SERINC5-3C- 
2XSTREP in pESG 
vector 
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2.3.3 Cell transfection 
The day prior to transfection, cells were seeded in 15 cm2 dishes at a density of 80-90% of confluence 
without antibiotics. 
30 μg DNA per dish was diluted in 9 ml Optimem serum-free medium (Gibco) together with 1 ml of 
0,1% linear PEI (Sigma-Aldrich). The mixture was incubated at room temperature for 15 minutes and 
then added to the cells. 
 
2.3.4 FLAG purification protocol 
Cell were collected, washed in PBS and lysed in lysis buffer (table 2) supplemented with 1% of 
detergent. A list of screened detergents is reported in table 3. The cell lysate was left rotating at 4°C 
for 2 hours. To remove cell debris, the lysates were ultracentrifuged at 31000rpm at 4°C for 1 hour. 
The supernatant was pre-cleared upon the incubation at 4°C for 30 minutes with GST-Sepharose 4 
fast flow beads (GE Healthcare Life Science) pre-equilibrated with lysis buffer. The samples were 
separated from the beads through a centrifugation step and then incubated with EZview red ANTI-
FLAG M2 beads (Sigma-Aldrich) pre-equilibrated with lysis buffer. After 2hrs incubation at 4°C, the 
supernatant was applied onto a gravity flow column. Unbound material was removed by washing 5 
times with washing buffer (table 2). The protein has been eluted by adding 0,5mg/ml FLAG peptide 
in washing buffer solution. 
 
2.3.5 STREP purification protocol 
Cell were collected, washed in PBS and lysed in lysis buffer (table 2) supplemented with 10% of 
detergent. A list of screened detergents is reported in table 3. The cell lysate was left rotating at 4°C 
for 2 hours. To remove cell debris, the samples were ultracentrifuged at 31000rpm at 4°C for 1 hour. 
The supernatant was pre-cleared upon the incubation at 4°C for 30 minutes with GST-Sepharose 4 
fast flow beads (GE Healthcare Life Science) beads pre-equilibrated with lysis buffer. The sample 
was separated from the beads through a centrifugation step and then incubated with Strep-Tactin 
Sepharose resin (iba) pre-equilibrated with lysis buffer. After overnight incubation at 4°C, the 
supernatant was applied onto a gravity flow column. Unbound material was removed by washing 5 
times with washing buffer (table 2). The protein has been eluted by adding 1mg/ml D-desthiobiotine 
(Sigma-Aldrich) in washing buffer. 
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Table 4. Buffers 
Lysis buffer 300mM KCl 
10mM Hepes pH7.5 
1 mM TCEP  
2 mM DTT  
1X protease inhibitor  
 
Washing buffer 300 KCl 
10mM Hepes pH7.5 
0.1% DDM 
1 mM TCEP 
2mM DTT  
 
Size Exclusion Chromatography Buffer 300 KCl 
10mM Hepes pH7.5 
0.03% DDM 
1 mM TCEP 
2mM DTT  
 
 
 
Table 5.  List of the screened detergents and their abbreviations 
Detergent Abbreviation 
Amidosulfobetaine-14 ASB-14 
3-(4-Heptyl)phenyl-3-hydroxypropyl-
dimethylammoniopropanesulfonate 
C7BzO 
CHAPS CHAPS 
n-Dodecyl D-maltoside DDM 
Octyl D-glucopyranoside OGP 
Octyl D-1-thioglucopyranoside OTP 
3-(Decyldimethylammonio)propanesulfonate SB-13 
Triton X-100 Triton-X100 
Octyl Glucose Neopentyl Glycol NPG-OG 
Lauryl Maltose Neopentyl Glycol NPG-DDM 
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2.3.6 Western Blotting 
A small aliquot of lysate from each step of both FLAG and Strep purification protocols have been 
resuspended in Laemmli buffer supplemented with 50mM TCEP pH7 (Sigma) and resolved by 12,5% 
SDS-PAGE. The primary antibodies used for recombinant SERINC5 detection in Western Blotting are 
reported in Table 5. 
 
Table 5.  Primary antibodies used for Western Blotting 
Name  animal source Dilution Reference 
ANTI-FLAG M2 
PEROXIDASE (HRP) 
mouse, monoclonal 1:3000 (Western Blotting) Sigma 
ANTI-STREP-TAG-II 
(ab76949) 
rabbit polyclonal 1:3000 (Western Blotting) abcam  
 
2.3.7 Size Exclusion Chromatography 
Eluted fractions were resolved by SDS-PAGE and SERINC5 containing flow-through fractions were 
combined and applied to a HiLoad 10/300 Superdex 200 pre-equilibrated with Size Exclusion 
Chromatography Buffer (table 2). The gel filtration column was operated on an AKTA purifier system 
at room temperature with a flow rate of 1ml/min. Separation efficiency and final purity were 
evaluated by SDS-PAGE analysis. SERINC5 containig fractions were pulled together, concentrated 
using an ultrafiltration device with a 100 kDa cutoff and shock frozen in liquid nitrogen for log-term 
storage at -80°C. 
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3.RESULTS 
  
80 
 
3.1 Nef counteracts a retrovirus inhibitor 
 
During the first year of my PhD I have been focused on studying the character of Nef requirement 
for HIV-1 infectivity. I have contributed to the optimization of the heterokaryon assay providing the 
evidence of the presence of a restrictive cellular activity counteracted by Nef, and to the 
identification of SERINC5 preparing RNA samples for sequencing (Figure 1 b, 1 c and 1 d, Extended 
Data Figure 1 e; Rosa et al., 2015).  
Before focusing completely on SERINC5, I have started a preliminary functional study on RNase H2B, 
another candidate gene proposed by the transcriptome analysis performed as potential HIV-1 
inhibitor (Figure 23).  
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Figure 23. Correlation of RnaseH2B expression in producer cells and Nef requirement for infectivity. The 
colors indicate the cell lines reported in Figure 1 a Rosa et al., 2015. Trendline indicates linear regression. 
(Pearson correlation, two-tailed, P<0,0001). RPM, reads per million 
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I have performed some experiments aimed to check the inhibitory action of RNase H2B on HIV-1 
through its ectopically expression in cells with minimal Nef-dependence like HT1080 and HEK293T 
cells. Since RNase H2B is not the catalytic subunit of the enzyme RNase H2, the two other subunits 
of RNase H (A and C) have been co-expressed to have a fully functional protein. The preliminary 
results obtained (Figure 22) failed to show a significant effect on HIV-1 infectivity. Since the 
preliminary functional data of SERINC5 revealed clearly and immediately its involvement in the 
effect of Nef on HIV-1 infectivity, the investigation involving RNAseH2B was therefore no further 
pursued. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 24. Infectivity of HIV-1 produced by HT1080 (a) and HEK293T cells (b) transiently expressing RNaseH2 enzyme. Virions limited 
to a single round of replication were produced transfecting HT1080 and HEK293T cells with pro-viral constructs together with plasmids 
expressing Env glycoproteins, Nef and the 3 different subunits of RNaseH. The infectivity of the viruses produced in presence and in 
absence of Nef has been tested on TZM-GFP reporter cells as described in Rosa et al, 2015.  
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3.2 SERINC5 and SERINC3 inhibit HIV-1  
In the second year of my PhD I have investigated the functional role of SERINC5 in infectivity and 
the molecular mechanism of Nef counteraction.  
My contribution consisted in the establishment of a SERINC5 knock out stable cell line, in the knock 
out of the gene in primary cultures (Figure 2 a, b and d, Extended data Figure 1 a, b; Rosa et al., 
2015), and in knocking out  all the other SERINC genes in Jurkat cells (Figure 2 h and I; Rosa et al., 
2015). I have also contributed in the developing of molecular constructs to allow a differential and 
gradual expression of SERINC5 (Figure 2 g; Rosa et al., 2015). 
 
3.3 Determinants of Nef activity against SERINC5 and 
conservation across different retroviruses 
I have tested the ability to counteract SERINC5 of different nef alleles, demonstrating the 
conservation of Nef activity among different primate lentiviruses (Figure 3 d; Rosa et al., 2015). I 
have also contributed to provide evidence of SERINC5 retrictive activity against MLV, which is 
evolutionary distant from HIV (Figure 3 e, f and g Rosa et al., 2015). 
 
3.4 Nef and glycoGag promote relocalization of SERINC5 to an 
endosomal compartment and prevent its incorporation into 
virions 
I have contributed to the evidence that the conservation of Nef activity among different primate 
lentiviruses results in the exclusion of SERINC5 from the viral particle (Figure 4 b and Extended Data 
Figure 2 a; Rosa et al., 2015). I have done also the part of the experiments supporting the indication 
that the exclusion of SERINC5 from the viral particles is performed also by glycoGag from MLV 
(Figure 4 c; Rosa et al., 2015). 
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3.5 SERINC5 inhibits an early step of virus infection 
During the third year of my PhD I was focused on the effect of SERINC5 in the target cells. I had the 
possibility to investigate this aspect thanks to the development of a new and more sensitive fusion 
assay in my laboratory. I had the chance to work both on the validation of the assay itself (Extended 
Data Figure 3 b; Rosa et al., 2015), together with my colleagues, and on its application to detect 
SERINC5 effect (Figure 5 e, Extended Data Figure 3 e; Rosa et al., 2015). 
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3.6 SERINC5 does not evolve under positive selection pressure 
 
The diversification under positive selection is a peculiarity of most restriction factors identified so 
far [reviewed by Duggal and Emerman, 2012]. In the last part of my PhD I tried to investigate the 
type of selective pressure exerted on SERINC5 gene evolution using a codon analysis method based 
on the comparison of the rates of non-synonymous (dN) (that alter the encoded amino acid) and 
synonymous (dS)  DNA changes between  different primate species has been used [Hurst, 2002].  
The ratio between the global synonymous changes per site (dS) and replacement changes per site 
(dN) for the tree (Figure 25) were calculated by a free-ratio model, which allows dN/dS to vary along 
different branches. The presence of positive selection is indicated by values grater than 1. In all the 
branches of the primate phylogeny constructed we found no evidence of positive selection on 
SERINC5 evolution (defined as dN/dS < 1.0). 
 
 
Figure 25 SERINC5 does not evolve under positive selection pressure. Codon analysis methods, based on comparing patterns of 
synonymous and nonsynonymous changes in protein coding sequences, were used to detect positive selection. The ratio between 
number of non synonymous substitutions and the number of synonymous substitutions (dN/dS) greater than 1 suggests that positive 
selection has acted along that lineage. The analysis was performed by CodeML software, which is part of PAML (Phylogenetic Analysis 
by Maximum Likelihood) suite. The phylogenetic tree was produced using MrBayes software. 
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3.7 Optimization of a purification protocol for SERINC5 protein 
 
The overexpression of human membrane proteins for purification purposes represents a great 
challenge. During this study, SERINC5 turned out to be a problematic protein to work with whenever 
its visualization by Western blotting was required. In a series of trial and error tests, we pinpointed 
the difficulties down to two prominent features of the protein: its hydrophobicity and its unusually 
high content of cysteines. Both such features contributed to form protein aggregates which were 
either lost during the process of protein extraction or failed to enter the SDS-PAGE. During the last 
three months of my PhD, I have been working in collaboration with Prof. Peter Cherepanov (Cancer 
Research UK) in order to develop and optimize a protocol to purify sufficient amount of soluble 
SERINC5 to undertake biochemical studies on the protein. 
Since mammalian cells provide a better tool for producing properly folded membrane proteins 
[reviewed by Tate, 2001], HEK293T cell line has been chosen as expression system for SERINC5.  
Human SERINC5 cDNA expressing a recombinant protein with a 3C protease recognition site 
followed by a FLAG and STREP tags in tandem fused at the C-terminus, was created by PCR and 
cloned in a pcDNA3.1 expression vector. Efficiency of expression in HEK293T cells transfected by PEI 
was assessed by Western blotting (Figure 26). 
In order to be purified, a membrane protein must be extracted from the membrane and maintained 
in a soluble form. To determine the suitable solubilization conditions, a small scale screen of 
detergent was performed [Chaudhary et al., 2011 and 2012]. The detergents tested are reported in 
Table 2. Detergents able to increase the ratio of the solubilized materials, indicated as “after spin” 
samples, relative to the total protein produced, reported as “before spin” samples, have been 
identified. DDM, NPG-OG and NPG-DDM detergents provided a higher % of solubilization of the 
protein compared to the other detergents (Figure 27) and they were selected for FLAG affinity 
purification experiments.  
Size exclusion chromatography has been used to assess the quality and the quantity of the 
solubilized protein. All the selected detergents showed the same chromatographic profile for the 
solubilized protein, with a monodisperse, included volume peak (Abs 280) revealing the presence of 
SERINC5. DDM clearly provided a larger yield of solubilized protein compared to the other 
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detergents screened (Figure 26), therefore it was chosen for the next FLAG affinity purification 
experiments. 
The FLAG purification protocol developed retrieved a modest amount of protein, which was lost in 
the different steps of the procedure, strongly affecting the final yield (Figure 28). This reduced 
capability of the -FLAG antibody to recognize SERINC5 tag might be due to the strong reducing 
conditions in which the purification has been performed in the attempt to reduce the high amount 
of cysteines of the protein. Such conditions ended up reducing, and therefore inactivating, the anti-
FLAG antibody. An alternative purification strategy without the use of antibodies has therefore been 
considered. Taking advantage of the STREP-tag present in addition to the FLAG tag, a parallel STREP 
purification was performed in the same samples. However, this strategy did not work, probably due 
to the reduced accessibility of the STREP tag in this construct. 
Another construct expressing SERINC5 with a double STREP-tag at the C-terminus has been 
produced and tested. STREP purification of SERINC5 was more efficient compared to the FLAG-Tag, 
showing a good depletion of the protein in the steps before elution and allowing the use of strong 
reducing conditions throughout the protocol (Figure 30).  
The sample was then injected for size exclusion chromatography and fractions of the desired peak 
were pooled together to concentrate the protein using an ultrafiltration device with a 100 kDa cutoff 
(Figure 31).  
So far, using this method, a sufficient amount of protein has been purified for biochemical 
characterization, whereas for structural studies a large scale production of the protein is still 
required. The establishment of a cell line constitutively expressing SERINC5 would be a less laborious 
and cost-effective approach for crystallization purposes. 
 
  
87 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
CTRL SER5-3C-Strep-FLAG 
#1 #2 #3 
SERINC5 
Figure 26. Expression levels of recombinant SERINC5. HEK293T transfected using PEI with three 
different molecular clones of human SERINC5-3C-Strep-FLAG in pcDNA3.1 vector were lysed in 
Laemmli buffer supplemented with 50mM TCEP pH7 and resolved by 12,5% SDS-PAGE after 5 
pulses of sonication. SERINC5 was immunoblotted using mouse monoclonal anti-FLAG M2 
PEROXIDASE HRP conjugated antibody. 
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Figure 27 Western blotting analysis of small-scale, whole cell solubilized SERINC5   
Human SERINC5-3C-Strep-FLAG recombinant protein has been solubilized from HEK293T cells transfected using PEI. 
Cells were resuspended in lysis buffer (see table 4) supplemented with 1% of each tested detergent (see table 5). The 
lysates were resuspended in Laemmli buffer supplemented with 50 mM TCEP pH7 and resolved by 12,5% SDS-PAGE. 
SERINC5 was immunoblotted using mouse monoclonal anti-FLAG M2 PEROXIDASE HRP conjugated antibody. For each 
detergent screened, the total amount of produced SERINC5 protein is reported in lanes B, while the amount of 
solubilized SERINC5 protein recovered after ultracentrifugation of the lysates is reported in lanes A. The CTRL lanes 
report whole cell lysates processed without detergents. DDM, NPG-OG and NPG-DDM detergents provided a higher 
% of solubilization of the protein compared to the other detergents. 
 
 
 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 13 14 11 15 16 17 18 
SEC collected fractions  
 
12 13 14 11 15 16 17 18 
12 13 14 11 15 16 17 18 
 
DDM 
solubilization 
  
NPG-DDM 
solubilization 
 
NPG-OG 
solubilization 
  
Figure 28. Western blotting analysis on Size Exclusion Chromatography (SEC) fractions 
collected after SERINC5 solubilization with the indicated detergents. Fractions collected 
during the Size Exclusion Chromatography of solubilized human SERINC5 protein from 
HEK293T cells transfected using PEI have been resuspended in Laemmli buffer 
supplemented with 50 mM TCEP pH7 and resolved by 12,5% SDS-PAGE. SERINC5 was 
immunoblotted using mouse monoclonal anti-FLAG M2 PEROXIDASE HRP conjugated 
antibody. Lanes are labeled with the elution volumes of the analyzed aliquots (11-18).  
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Figure 29.  Western blotting analysis to detect recombinant SERINC5 in different steps of FLAG purification 
protocol. Human SERINC5-3C-Strep-FLAG recombinant protein has been solubilized from HEK293T cells 
transfected using PEI. Cells were resuspended in lysis buffer (see table 4) supplemented with 1% of DDM (see 
table 5). Cell lysates  collected after clarification via ultracentrifugation (lanes A), incubation with GST-
sepharose beads (lanes B) and  incubation with anti-FLAG M2 beads (lanes C) were resuspended in Laemmli 
buffer supplemented with 50 mM TCEP pH7 and resolved by 12,5% SDS-PAGE. Unbound material removed 
through washing steps of anti-FLAG M2 beads (lanes D) and eluted SERINC5 recombinant protein (1:20 diluted) 
from anti-FLAG M2 beads were resolved by SDS-PAGE accordingly. SERINC5 was immunoblotted using mouse 
monoclonal anti-FLAG M2 PEROXIDASE HRP conjugated antibody. Each sample was loaded twice. 
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Figure 30.  Western blotting analysis to detect recombinant SERINC5 in different 
steps of STREP purification protocol. Human SERINC5-3C-Strep-FLAG recombinant 
protein has been solubilized from HEK293T cells transfected using PEI. Cells were 
resuspended in lysis buffer (see table 4) supplemented with 1% of DDM (see table 
5). Cell lysates  collected after clarification via ultracentrifugation (lanes A), 
incubation with GST-sepharose beads (lanes B) and  incubation with Strep-tactin 
sepharose beads (lanes C) were resuspended in Laemmli buffer supplemented with 
50 mM TCEP pH7 and resolved by 12,5% SDS-PAGE. Unbound material removed 
through washing steps of Strep-tactin sepharose beads (lanes D) and eluted SERINC5 
recombinant protein (1:20 diluted) from Strep-tactin sepharose beads were resolved 
by SDS-PAGE accordingly. SERINC5 was immunoblotted using mouse monoclonal 
anti-FLAG M2 PEROXIDASE HRP conjugated antibody. Each sample was loaded twice. 
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Figure 31. Coomassie blue staining on purified SERINC5 recombinant protein. Selected fractions of the 
desired peak collected during the Size Exclusion Chromatography of purified human SERINC5-3C-Strep-
FLAG recombinant protein from HEK293T cells have been pooled together and concentrated using an 
ultrafiltration device with a 100 kDa cutoff. Sample before concentration (lane 1), after concentration (lane 
2) and flowthrough (lane 3) were resuspended in Laemmli buffer supplemented with 50 mM TCEP pH7, 
resolved by 12,5% SDS-PAGE and stained with Coomassie blue (Instant blue Expedeon). 
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4. DISCUSSION 
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A first step towards the understanding of the mechanism behind the Nef requirement for optimal 
HIV infectivity dates back to the mid-1990s, when Nef was reported to mediate HIV-1 infectivity 
enhancement upon its expression in producer cells rather than in target ones [Aiken and Trono, 
1995]. In particular, Nef expression is particularly important in lymphoid cell lines to produce fully 
infectious viruses [Pizzato, 2010], suggesting a cell-type dependency of the Nef requirement for 
infectivity. Starting from these observations, a quantification of the extent to which Nef affects the 
infectivity of HIV-1 virions produced from 31 human cell lines of different histological origin has 
been performed (Figure 1 a and Table 1, Rosa et al., 2015). The Nef effect shows high variability, 
ranging from 2 to 40-fold depending on the producer cell type. Interestingly, in some lymphoid cell 
lines such as CEMX174, MT4 and DAUDI, Nef seems to be dispensable for the production of 
optimally infectious virions. Given the marked cell-type specificity, it appeared conceivable that the 
observed variability could be due to a differential expression of one or more cellular components, 
providing two different possibilities: Nef could either counteract a dominant cellular HIV-1 inhibitor 
expressed in cell lines with high Nef requirement or conversely, Nef could promote the expression 
of a cellular co-factor missing in those cells and require Nef for optimal HIV-1 infectivity. To 
understand the nature of the sought host factor a heterokaryon assay has been established (Figure 
1 b, Rosa et al., 2015). This kind of assays has been used in previous studies as complementation 
assay to identify the character of specific phenotypes shown by different cell types [Mehle and 
Doudna, 2008; Varthakavi et al., 2003; Simon et al, 1998; Dragic et al., 1992; Madani and Kabat, 
1998]. Thus, heterokaryons derived from cell lines with opposite Nef-requirements have been used 
to produce Nef-positive and Nef-negative HIV-1 virions. The resulting high dependence on Nef of 
HIV-1 virions produced by heterokaryons (Figure 1 c, Rosa et al., 2015) indicated the presence of a 
trans-dominant cellular inhibitor of HIV-1 infectivity expressed in cells with high Nef-responsiveness. 
This therefore revealed that Nef is required to counteract a potential restrictive cellular activity in 
those cells. The subsequent quantification of the global transcriptome in a panel of cell lines 
characterized by different Nef dependence, has revealed the best correlation (r= 0,945) between 
the requirement of Nef and SERINC5 expression (Figure 1 d, Rosa et al., 2015). The expression of 
other candidate genes such as RNase H2B (r=0,935) and ZNF643 (r=0,938) has shown a good 
correlation as well (Figure 30). However, despite the similarly good degree of correlation, only 
expression of SERINC5 could predict Nef responsiveness with no exception. In contrast, other genes 
(such as RNaseH2B and ZNF643) were found to be equally expressed in some Nef responsive as well 
in some Nef-non responsive cell lines. RNase H2B is a subunit of RNaseH2, an endonuclease that 
92 
 
specifically degrades the RNA of DNA:RNA hybrids. Interestingly, RNaseH2 was found implicated in 
the Aicardi Goutièrs Syndrome [Crow and Rehwinkel, 2009] together with SAMHD1 [Hrecka et al., 
2011; Laguette et al., 2011], a retroviral restriction factor, and TREX1, which was found to target 
retroviral cDNA in the cytoplasm [Yan et al., 2010]. Due to this possible functional relation, the ability 
of RNase H2 to inhibit HIV-1 infectivity was investigated. The preliminary results obtained (Figure 
22 Result chapter) failed to show a significant effect of RNAse H2B overexpression on infectivity. In 
contrast, the early experiments in which SERINC5 was knocked out or overexpressed revealed 
clearly and immediately its involvement in the effect of Nef. The investigation involving RNAseH2B 
was therefore no further pursued. 
 
 
 
 
 
 
 
SERINC5 is highly expressed in cells with strong Nef responsiveness, like the lymphoid Jurkat cell line 
(Figure 1 d, Rosa et al., 2015). A comparable level of gene expression is detectable also in primary 
blood cells from three different donors (PBMC) (Extended data Figure 1 c, Rosa et al., 2015), 
suggesting SERINC5 activity in the primary targets of HIV infection in vivo. Functional studies have 
then confirmed SERINC5 as a powerful host inhibitor of HIV-1 infectivity counteracted by Nef (Figure 
2 a – g, Extended figure 1 a - d, Rosa et al., 2015). 
SERINC5 belongs to a unique family of gene made up of five members in H. sapiens [Grossman et 
al., 2000; Xu et al., 2003]. It was suggested that SERINC proteins mediate the incorporation of serine 
into membrane lipids [Inuzuka et al, 2005], hence the name “Serine Incorporators”, but their 
function is still unknown. The family is conserved in eukaryotes with a predictive membrane 
topology containing 10 putative transmembrane helices [Inuzuka et al, 2005; Xu et al., 2003]. The 
five members of the human SERINC family share more than 17% amino acid identity and a similar 
predictive membrane topology (Figure 31). 
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Figura 32. Correlation of SERINC5 , ZNF643 and RNaseH2B in producer cells and Nef requirement. The colors indicate 
the cell lines reported in Figure 1 a from Rosa et al., 2015. Trendline indicates linear regression. (Pearson correlation, two 
tailed, P>0,0001). RPM, reads per million. 
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 In addition to SERINC5, other members of SERINC gene family are expressed in Nef responsive cell 
lines, like the lymphoid Jurkat cell line (Extended Figure 1 e, Rosa et al., 2015). Therefore, the 
functional study in the context of HIV-1 infectivity has been extended also to the the other members 
of SERINC gene family, leading to the identification of SERINC3 as another HIV-1 inhibitor 
counteracted by Nef. However, SERINC3 effect on virions infectivity is not as powerful as the one 
exerted by SERINC5 (Figure 2 h – i, Rosa et al., 2015). 
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Figure 33. Predictive membrane topology of SERINC family members. 
The analysis has been performed using TOPCONS tool. 
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In order to counteract the SERINC5 restrictive activity, Nef needs specific molecular determinants. 
Mutations affecting Nef myristoylation (G2A) impair its ability to target SERINC5 (Figure 3 a, Rosa et 
al., 2015), suggesting that the importance of Nef ability to interact with membranes is important for 
the enhancement of HIV-1 infectivity. Moreover, Nef interaction with factors involved in clathrin-
dependent intravesicular trafficking like dynamin 2 and AP2, reported to be required for HIV-1 
infectivity enhancement [Pizzato et al., 2007; Craig et al., 1998], are necessary for SERINC5 
counteraction as well (Figure 3 a and 4 f, Rosa et al., 2015). Immunofluorescence microscopy data 
show that SERINC5 is predominantly localized on the plasma membrane (Figure 4 g, Rosa et al., 
2015) and is relocalized in late endosomes by Nef (Figure 4 h, Rosa et al., 2015), explaining the 
dependence of Nef activity on the endocytosis machinery. By decreasing SERINC5 cell surface levels, 
Nef prevents its incorporation into the nascent viral particles (Figure 4 a, Rosa et al., 2015). Nef 
mutants unable to interact with members of the endocytosis pathway fails to exclude SERINC5 from 
virions (Figure 4 a, Rosa et al., 2015), underlying the crucial role of intracellular trafficking for Nef 
activity on viral infectivity. Interestingly, among the Nef mutants analysed, those which fail to 
counteract SERINC5 are also known to be defective for CD4 down modulation (G2A, LL165,166AA, 
D123A), (Figure 3 a, Rosa et al., 2015), allowing us to speculate that the molecular mechanism 
employed by Nef to internalize both CD4 and SERINC5 could be the same. 
Another important determinant affecting the magnitude of the Nef requirement for optimal HIV-1 
infectivity is the nature of the envelope glycoprotein expressed on the viral surface [Pizzato, 2010; 
Miller et al., 1995; Aiken, 1997; Chazal et al, 2001; Pizzato et al., 2008; Luo et al., 1998]. HIV-1 
pseudotyping with glycoproteins able to relieve the need for Nef in the infection process, like VSV 
and EBOV, makes the virus resistant to SERINC5 (Figure 3 b, Rosa et al., 2015). The absence of 
infectivity inhibition, despite SERINC5 being incorporated into viral pseudotyped particles (Figure 4 
d and e, Rosa et al., 2015), suggests that these glycoproteins offer an alternative mechanism to 
antagonize the SERINC5 inhibitory effect. One possibility is that the entry step mediated by those 
envelope glycoproteins may help the virus to override the SERINC5 block, explaining the dispensable 
role of Nef. 
The dependence of the Nef activity on the nature of the envelope glycoprotein has been reported 
also when HIV-1 is pseudotyped with Env from HIV-1 naturally occurring strains [Usami and 
Göttlinger, 2013; Lai et al., 2011]. A recent report has shown a relatively weak Nef responsiveness 
of some primary Envs compared to Env glycoproteins of laboratory-adapted strains [Usami and 
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Göttlinger, 2013]. Interestingly, some HIV-1 envelope glycoproteins from clinical isolates appeared 
to modulate the susceptibility of the virus to SERINC5 inhibition (Figure 3 c, Rosa et al., 2015); 
suggesting the possibility that in some isolates HIV-1 might use Env in addition to Nef to antagonize 
SERINC5.  
The Nef requirement for the early stages of infection [Aiken and Trono, 1995; Chowers et al., 1995; 
Schwartz et al, 1995] is mirrored by the inhibitory action of SERINC5 soon during the infection 
process. The presence of SERINC5 in HIV-1 virions impairs their ability to accumulate reverse 
transcription products in the target cells (Figure 5 a, Rosa et al., 2015), suggesting an early block. 
The potential effect of Nef on viral entry has been widely debated, remaining unsolved so far [Day 
et al., 2004; Cavrois et al., 2004; Tobiume et al., 2003]. The development of a novel and sensitive 
fusion assay, based on the detection of the Cre protein delivered to the nucleus of the target cells 
independently of productive infection (Figure 5 b, Extended Data Figure 3 a and b, Rosa et al., 2015), 
has addressed this question. SERINC5 incorporation into virions impairs the ability of Cre to access 
the target cells. We have  consolidated this observation also using another assay (delivery of Vpr-
BLAM) which has been used in previous reports [Cavrois et al., 2002; Cavrois et al., 2004; Day et al., 
2004] (Extended Data Figure 3 d, Rosa et al., 2015). However, the magnitude of this defect is ten-
fold lower compared to the powerful inhibition of infectivity mediated by SERINC5 (Figure 5 c and 
e, Extended data 5 f, Rosa et al., 2015). Considering that Cre is a small protein (40 kDa), it is possible 
to hypothesize that SERINC5 exerts a bigger effect in the translocation of a larger protein complex 
like the viral core (60-120 nm) into the target cells. Therefore, since fusion between the viral particle 
and the target cells remains detectable in the presence of SERINC5, the host inhibitor might target 
a post-fusion event required for the translocation of the viral core into the target cells. Membrane 
fusion is a multi-step process, where the expansion of the fusion pore is reversible and represents 
the highest energy requiring stage [Chanturiya et al., 1997; Cohen and Melikyan, 2004]. Once 
formed, the fusion pore may close again or expand further until the expansion becomes irreversible 
(Figure 32). While fusogenic proteins might promote the enlargement of a fusion pore by reducing 
the energy barrier required, membrane proteins, such as SERINC5, may inhibit fusion by increase 
the same barrier [Chanturiya et al., 1997]. 
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Figure 34 Sequential steps in phospholipid membrane fusion. From Chanturiya et al. PNAS 1997;94:14423-14428 
 
The lipid composition also sets the e nergy barrier necessary to enlarge the fusion pore [Ciechonska 
et al, 2014; Razinkov et al, 2000; Chanturiya et al., 1997]. It is therefore possible to speculate that 
the effect on fusion pore enlargement could be due to the influence of SERINC5 on the membrane 
composition rather than to the presence of the protein itself. The envelope glycoproteins may 
actually reduce the energy barrier required for the enlargement of fusion pore to allow the 
translocation of the viral content in the target cells. Indeed, HIV-1 pseudotyped with envelope 
glycoproteins like VSV-G and EBOV GP, are able to perform productive infection without preventing 
SERINC5 incorporation into viral particles (Figure 3 b, 5 d, 4 d and e, Rosa et al., 2015), in line with 
the dispensable effect of Nef on the infectivity of such pseudotypes. However, the presence of 
proteins altering the rigidity and the curvature of the lipid bilayer might also affect the expansion of 
the fusion pore [Chen et al., 2008], including the possibility that the incorporation of SERINC5 into 
the viral particles may account for this effect as well.  
On the other hand, it has been suggested that the envelope glycoproteins which render HIV high 
Nef responsive require a high potential energy to mediate fusion [Medjahed et al, 2013; Usami and 
Göttlinger, 2013]. The amount of such energy is associated with the clustering of Env trimers 
[Brandenberg et al., 2015; Usami and Göttlinger, 2013] mapped on HIV-1 surface and at virus-cell 
contact regions [Chojnacki et al., 2012; Sougrat et al., 2007]. The clustering of Envelope trimers 
might therefore be disturbed by either the presence of SERINC5 itself on the viral surface or by the 
altered lipid composition. These speculations are also consistent with the proposed role of Nef in 
enhancing the cytoplasmic delivery of the viral core [Schaeffer et al., 2001]. At the moment it 
remains unknown whether SERINC5 alters the lipid composition of the viral envelope leaving the 
question open.  
SERINC5 is expressed in HIV-1 target cells in vivo (Extended Figure 1 c and Extended Figure 4, Rosa 
et al., 2015), where the cell-to-cell transmission mechanism could be important [Jolly et al., 2004]. 
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Cell-to-cell transmission of HIV-1 throughout a culture is extremely efficient compared to 
transmission via cell-free virus [Jolly et al., 2004; Sourisseau et al., 2007]. The positive effect of Nef 
on viral replication in vivo has been confirmed by different reports [Kim et al., 1989; Jamienson et 
al., 1994; Deacon et al, 1995], while its effect on spreading infection in vitro is still unclear. Recent 
studies have reported only a marginal effect of Nef in cell-to-cell mediated HIV-1 transmission 
without affecting the formation of contact sites between cells known as virological synapses 
[Malbec et al., 2013; Haller et al., 2011].  
Because of a comparable expression of SERINC5 in PBMCs and in the cell line like Jurkat, a similar 
potential in restricting viral replication could be expected. The investigation of SERINC5 and SERINC3 
effect on HIV-1 spreading in Jurkat cell lines has confirmed their restrictive activity, even if the 
magnitude of the effect observed does not mirror the powerful block on infectivity [Usami et al., 
2015]. Considering the strong requirement of Nef for viral replication in vivo, it would be worth to 
assess the SERINC5 and SERINC3 restrictive role in the context of spreading infection of human 
primary cultures. This information is still missing since obtaining a stable SERINC5 -/- primary culture 
to assess spreading infection is quite challenging. Further work is needed to fully understand 
whether cell-to-cell spread of HIV-1 is susceptible to SERINC5 mediated restriction in the absence 
of Nef. However albeit modest, the Nef ability to enhance viral cell-to-cell transfer was reported to 
be conserved among primate lentiviruses [Malbec et al., 2013; Münch et al., 2007] like the 
counteraction of SERINC5 restrictive activity (Figure 3 d, 4 b, Extended data Figure 2, Rosa et al., 
2015). A potential effect of SERINC5 cell-to-cell transfer and therefore in viral replication in vivo is 
plausible. 
 SERINC5 might be involved in the induction of an intracellular innate response in the target cells, as 
observed for other host antiviral factors such as BST-2 and TRIM5[Pertel et al., 2011, Galão et al., 
2012]. SERINC5 may also work as a pathogen recognition molecule detected on viral particles by 
specific cellular components, which in turn may trigger a proinflammatory response. This hypothesis 
implies the existence of a possible “cellular receptor” recognizing SERINC5 on the viral surface. 
SERINC5 and SERINC3 have been listed as restriction factors [Kluge et al., 2015], although they show 
features that do not reflect the classic hallmarks of the antiviral factors identified so far.  
In contrast to most antiviral factors reported in literature, SERINC5 and SERINC3 expression in 
primary CD4+ T cells or dendritic cells is not upregulated neither by type I interferon nor by an 
interferon inducing agent (Extended data Figure 4, Rosa et al., 2015). Thus, SERINC5 and SERINC3 
are examples of constitutively expressed intrinsic restriction factors. 
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Another peculiarity of most restriction factors is their diversification under strong positive selection 
[Duggal and Emerman, 2012]. Throughout the evolution, the exposure of a host restriction factor to 
a viral threat and the consequent interaction with the viral antagonist result in a positive selection 
signature on the host gene sequence and on the viral counterpart as well (Figure 35 a) [Duggal and 
Emerman, 2012]. This kind of selective pressure is characterized by an excess rate of non-
synonymous mutations (dN) compared with synonymous mutations (dS), as consequence the dN/dS 
ratio is generally high at the level of single amino acid residues directly involved in the viral 
restriction and across the entire protein coding sequence (Figure 35 b). A method based on the 
estimation of the dN/dS ratio has been used to evaluate a potential positive selective pressure on 
SERINC5 evolution. In line with SERINC5 high degree of conservation in eukaryotes [Grossman et al., 
2000; Inuzuka et al., 2005], its alleles in different primate species taken into consideration do not 
show any positive selection in the coding sequence (Figure 23). This represents another peculiar 
feature in contrast with other anti-retroviral  factors. 
 
 
Figure 35.  Genetic conflict between virus and host. From Duggal and Emerman, 2012, Nature Reviews – Immunology, 12, 686-695 
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The SERINC gene family is highly conserved, since an ortholog is present also in yeast. A core 
biological function of SERINC5, however, remain unclear. Furthermore, the presence of five SERINC 
genes in human species is likely the result of gene duplication, which often implies 
subfunctionalization, in which only one gene retains the essential cellular function while the 
paralogues might develop further functions [Duggal and Emerman, 2012]. Therefore, SERINC5 and 
SERINC3 antiviral activity might represent just an additional role of this family of proteins in the cell 
biology. On the other hand, an attractive hypothesis is that the increase of SERINC gene copy 
number might be a strategy of the host to restrict different viruses. Since primate restriction factors 
have been reported to prevent cross-species transmission events in vivo [Kirchhoff, 2010], it would 
be interesting to check the susceptibility of HIV-1 and other retroviruses to SERINC5 from different 
eukaryotic species in order to test whether the antiviral activity is conserved and whether it shows 
specie-specificity. 
The evidence that the SERINC5 counteracting activity is conserved among nef alleles of different 
primate lentiviruses (Figure 3 d, 4 b, Extended data Figure 2, Rosa et al., 2015) and shared with 
glycoGag from a retrovirus (MLV)  evolutionary distant from HIV (Figure 3 e – g; Figure 4 c; Extended 
Data figure 2 b, Rosa et al., 2015), highlights a fundamental role in the virus-host interaction. Given 
this example of convergent evolution of factors antagonizing the same restrictive cellular activity, it 
is possible that other viruses may be targeted by SERINC5 and have in turn evolved a counteracting 
agent.  
The massive HIV-1 inhibition exerted by SERINC5 when ectopically expressed despite the presence 
of Nef (Figure 2 g, Rosa et al., 2015), indicates its potential exploitation as an anti-HIV gene therapy 
factor. Interfering with the ability of Nef to downregulate SERINC5 could also represent a potential 
strategy to fight AIDS. For this purpose, a better understanding of the mechanism by which Nef 
downregulates SERINC5 is required. It remains to be established whether the two proteins interact 
directly. Having failed to detect positive selection within SERINC5, it could imply that no specific 
domains of the protein are directly involved in Nef interaction, suggesting the implication of other 
cellular factors. I have developed a purification protocol for SERINC5 which represents the first 
important step required to understand whether SERINC5 and Nef interact directly, and, if so, to 
identify the an interface that can be targeted by novel antiviral drugs. 
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HIV-1Nefpromotes infectionbyexcluding
SERINC5 from virion incorporation
Annachiara Rosa1*, Ajit Chande1*, Serena Ziglio1*, Veronica De Sanctis2, Roberto Bertorelli2, Shih Lin Goh3, Sean M. McCauley3,
Anetta Nowosielska3, Stylianos E. Antonarakis4,5, Jeremy Luban3, Federico Andrea Santoni4 & Massimo Pizzato1
HIV-1 Nef, a protein important for the development of AIDS, has well-characterized effects on host membrane
trafficking and receptor downregulation. By an unidentified mechanism, Nef increases the intrinsic infectivity of
HIV-1 virions in a host-cell-dependent manner. Here we identify the host transmembrane protein SERINC5, and to a
lesser extent SERINC3, as a potent inhibitor of HIV-1 particle infectivity that is counteracted by Nef. SERINC5 localizes to
the plasma membrane, where it is efficiently incorporated into budding HIV-1 virions and impairs subsequent virion
penetration of susceptible target cells. Nef redirects SERINC5 to a Rab7-positive endosomal compartment and thereby
excludes it from HIV-1 particles. The ability to counteract SERINC5 was conserved in Nef encoded by diverse primate
immunodeficiency viruses, aswell as in the structurally unrelated glycosylated Gag frommurine leukaemia virus. These
examples of functional conservation and convergent evolution emphasize the fundamental importance of SERINC5 as a
potent anti-retroviral factor.
Nef is a 27–32-kilodalton (kDa) protein expressed uniquely by prim-
ate lentiviruses that has a fundamental role in virus replication and the
development of AIDS1–3. It is a multifunctional factor that performs a
plethora of activities within the cell, among which is the ability to
downregulate crucial cell surface molecules (including CD4, MHC-I
and T-cell receptor) via interaction with vesicular trafficking
machinery4. Other activities of Nef include the ability to alter the
activation state of T cells and macrophages5–8 and to perturb the actin
cytoskeleton9 by engaging with cellular kinases. These relatively well-
characterized activities, however, do not explain another function of
Nef that was reported 20 years ago10, that is, its ability to enhance the
infectivity of the virion. The latter activity seems to be important for
HIV-1 pathogenesis because it is phylogenetically conserved among
widely divergent primate lentiviruses11 and maintained under strong
selective pressure during disease progression12. Such enhancement of
virion infectivity depends on nef being expressed from within virus-
producing cells13, but it is manifest at an early stage in the subsequent
infection of susceptible target cells13–15, indicating a yet unknown
modification of progeny virus particles.
Although Nef is unique to HIV and SIV, glycosylated Gag from an
unrelated gammaretrovirus (Moloneymurine leukaemia (MLV)) fully
substitutes for the activity of Nef on HIV-1 infectivity16. Despite the
lack of any sequence homology, Nef and glycosylated Gag share a
remarkable functional similarity, as they both require host cell
endocytosis machinery to boost virion infectivity17. A Nef-like activity
promoting retrovirus infectivity has therefore arisen by convergent
evolution within an unrelated family of retroviruses. However, the
molecular mechanism underlying the requirement of Nef and glyco-
sylated Gag for retrovirus infectivity has so far remained elusive.
Nef counteracts a retrovirus inhibitor
We investigated towhat extent theNef requirement for virion infectivity
is producer cell-type dependent, by comparing the infectivity of wild-
type HIV-1 to its Nef-defective counterpart produced from 31 different
human cell lines (Fig. 1a and Extended Data Table 1). Varying with the
producer cell type, the effect of Nef ranged from 2- to 40-fold, arguing in
favour of the presence of a cellular inhibitor of HIV-1 counteracted by
Nef.We then investigatedwhether thisNef responsiveness is a dominant
feature in producer cells by generating Nef-positive and Nef-negative
HIV-1 virions from heterokaryons derived from cell lines with opposite
Nef-responsiveness (Fig. 1b). When lymphoid cells (high Nef respons-
ive) were fused with fibrosarcoma cells (low Nef responsive), HIV-1
produced by heterokaryons displayed relatively high dependence on
Nef (Fig. 1c), indicating the presence of a transdominant cellular inhib-
itor of HIV-1 infectivity counteracted by Nef.
To identify such a putative host factor, the global transcriptome
of high and low Nef-responsive cells was examined to pinpoint dif-
ferentially expressed genes that correlate with Nef responsiveness.
Transcriptomes from seven highly Nef-responsive cell lines (Nef
effect ranging from 10- to 40-fold) and eight low Nef-responsive
cell lines (Nef effect lower than fourfold) were subjected to RNA-
sequencing (RNA-seq). On the basis of correlation analysis,
SERINC5 emerged as the gene whose expression correlated best with
the requirement of Nef for HIV-1 infectivity (Fig. 1d).
SERINC5 inhibits HIV-1 and MLV
To validate functionally the effect on virion infectivity, the SERINC5
genomic sequence was disrupted in the cell line with the highest
Nef responsiveness (Jurkat TAg or JTAg) using a clustered regularly
interspaced short palindromic repeat (CRISPR)-Cas9 lentiviral
vector (Extended Data Fig. 1a). SERINC5 knockout cells produced
a 20–30-fold increase in the infectivity of the Nef-defective HIV-1,
whereas the Nef-positive virus was only affected 2–3-fold, thus
reducing the Nef effect from 50- to 3-fold (Fig. 2a, b). This result
was reproduced targeting three different regions of the SERINC5
gene (Extended Data Fig. 1b). When haemagglutinin (HA)-tagged
SERINC5 was expressed from a complementary DNA non-targetable
by the CRISPR-Cas9 vector, the high Nef-dependent phenotype was
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restored (Fig. 2c), and the infectivity of the Nef-defective HIV-1 was
reduced 197-fold versus a fivefold only reduction of the Nef-positive
counterpart. SERINC5 was found to be expressed in primary blood
cells from three different donors to a level comparable to that
observed in Jurkat cells (Extended Data Fig. 1c). Accordingly,
CRISPR-Cas9 vector-mediated SERINC5 knockout cells increased
specifically the infectivity of Nef-defective HIV-1 produced in cul-
tured peripheral bloodmononuclear cells (PBMC) derived from three
different individuals (Fig. 2d), demonstrating that SERINC5 inhibits
HIV-1 produced in primary human blood cells.
Ectopic expressionof SERINC5 in cellswithminimalNef-dependence
(Fig. 2e, f and Extended Data Fig. 1d), resulted in a 10–40-fold selective
inhibition of Nef-defective HIV-1. SERINC5 is therefore not only
required, but also sufficient to inhibit HIV-1 infectivity and to confer
Nef responsiveness. While inhibition of HIV-1 infection by SERINC5 is
dose-dependent (Fig. 2g), the ability of Nef to preserve the infectivity of
the virus particle is abolished with increasing expression of SERINC5,
suggesting that the ability of Nef to counteract SERINC5 is saturable
(Fig. 2g). At the highest SERINC5 expression level, virion infectivity was
reduced 256-fold, regardless of Nef expression.
SERINC5 belongs to a unique gene family present in all eukaryotes
and contains 10 putative transmembrane helices18,19. While it was
suggested that SERINC proteins mediate incorporation of serine into
membrane lipids20, their function is unknown. The five members of
the human SERINC family share more than 17% amino acid identity
and a similarly predictedmembrane topology.We observed that virus
produced in JTAg SERINC52/2 cells retains a 2–3-fold responsive-
ness to Nef (Fig. 2a). Our transcriptome analysis indicated that JTAg
cells express other SERINC genes in addition to SERINC5 (Extended
Data Fig. 1e). We therefore explored the possibility that other
SERINC family members have anti-HIV-1 activity by knocking out
the five SERINC genes individually. Targeting SERINC3 in JTAg
SERINC52/2 cells resulted in a 2–3-fold rescue of Nef-defective virus
infectivity (Fig. 2i), thus further reducing the residual Nef responsive-
ness to 1.6-fold (Fig. 2i). Ectopic expression of SERINC3 resulted in
threefold inhibition of Nef-defective HIV-1 (Fig. 2i), confirming that
SERINC3 can also inhibit HIV-1 infectivity.
The Nef activity against SERINC5
The effect of Nef on infectivity requires Nef myristoylation and inter-
action with clathrin-mediated endocytosis21,22 (AP2 and dynamin2).
Accordingly, the ability to counteract SERINC5 was impaired by
nef mutations that abolish Nef amino-terminal myristoylation
(G2A), disrupt a di-leucine-based sorting signal (LL165AA) necessary
for AP2 interaction21, or prevent binding to dynamin 2 (D123A,
Fig. 3a)22. By contrast, mutations abrogating either a proline-rich
SH3 binding domain (PP75AA)23, or di-acidic motif required for
CD4 downregulation (EE156QQ)24, do not affect the ability to
counteract SERINC5 (Fig. 3a). The molecular features of Nef already
known to be crucial for the effect on infectivity are therefore required
for counteracting SERINC5.
It has been reported that the effect of Nef on infectivity depends on
the nature of the envelope glycoprotein16,25–29. Accordingly, pseudo-
typing HIV-1 with vesicular stomatitis virus G protein (VSV-G) and
with the Ebola virus glycoprotein (EBOV GP), but not with MLV-A
nor MLV-X Env, makes HIV-1 resistant to SERINC5 (Fig. 3b). The
magnitude of the effect of Nef on infectivity was also reported to vary
when HIV-1 is pseudotyped with envelope glycoproteins derived
from different HIV-1 isolates30,31. Accordingly, virions carrying Env
derived from a panel of HIV-1 primary isolates were variably affected
by SERINC5 (Fig. 3c), indicating that naturally occurring isolates are
inhibited by the host factor to different extents.
The activity of Nef on infectivity is highly conserved among prim-
ate lentiviruses11. We therefore tested whether the ability to counter-
act SERINC5 is shared among nef alleles. Nef proteins derived from
subtypes B, C, D and F clinical isolates could counteract ectopically
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expressed SERINC5–HA with a potency 5–10-fold higher than
that observed with Nef derived from a laboratory adapted strain
(HIV-1LAI, Fig. 3d). Similarly, Nef from two divergent SIV lineages
(SIVmac239 and SIVagm) also counteracted SERINC5 with tenfold
higher efficacy than HIV-1LAI (Fig. 3d). The ability to counteract
SERINC5 is therefore a prominent feature of Nef, conserved across
different primate lentivirus species.
We next tested whether SERINC5 can target retroviruses other
than lentiviruses. We have shown that glycosylated Gag (glycoGag)
from MLV is capable of rescuing the infectivity of Nef-defective
HIV-1 (ref. 16), despite sharing no sequence homology with Nef.
Indeed, glycoGag efficiently rescues the infectivity of HIV-1
(Fig. 3e) by counteracting SERINC5, suggesting that SERINC5 has
an important role also in the context of infection with gammaretro-
viruses. Accordingly, SERINC5 expression in producer cells potently
inhibited infectivity of MLV only in the absence of glycoGag
(Fig. 3f, g). Therefore, while SERINC5 targets divergent retroviruses,
factors capable of overcoming its inhibitory activity on infectivity
have evolved independently.
Incorporation of SERINC5 into virions
The ability of SERINC5 to be incorporated into the lipid envelope of
HIV-1 virions was tested next. HIV-1 was produced in JTAg
SERINC52/2 expressing SERINC5–HA. Despite being barely detect-
able in cells in the absence of Nef, SERINC5–HA was readily visua-
lized in Nef-defective virions and was largely excluded from virions
generated in the presence of Nef (Fig. 4a) but not in the presence of the
Nef mutant lacking the AP2 binding site (LL165AA, Fig. 4a). The
ability to prevent virion incorporation of SERINC5 was readily
observed with Nef alleles from HIV-1 and SIV (Fig. 4b) and with
MLV glycoGag (Fig. 4c), suggesting that association with virions is
crucial for the effect on infectivity and is tightly controlled by both
primate lentiviral and gammaretroviral factors. The effect of Nef
on SERINC5 association with virions did not alter the amount of
incorporated Env (Extended Data Fig. 2a), in line with previous
observations that failed to observe any effect of Nef on virion Env
abundance16,25,31. By contrast, the amount of SERINC5 incorporated
into HIV particles was not reduced by VSV-G (Fig. 4d) nor by EBOV
GP (Fig. 4e), despite the infectivity of VSV-G and EBOV GP pseudo-
types being resistant to the host factor (Fig. 3b). Therefore, while Nef
and glycoGag seem to counteract SERINC5 by preventing its incorp-
oration into virions, VSV-G and EBOV GPmust antagonize its effect
by a different mechanism.
The ability of Nef to counteract SERINC5was significantly reduced
by silencing AP2 (Fig. 4f), confirming the crucial involvement of
clathrin-dependent intravesicular trafficking. Using immunofluores-
cence microscopy, green fluorescent protein (GFP)-tagged SERINC5
(Fig. 4g) was observed to localize almost exclusively to the plasma
membrane. By contrast, the expression of HIV-1 Nef caused
SERINC5 to relocalize together with Nef into perinuclear vesicles
identified as late endosomes (RAB7-positive, Fig. 4h). SERINC5
was similarly efficiently retargeted into perinuclear vesicles by SIV
Nef and by MLV glycoGag (Extended Data Fig. 2b), indicating a
common ability of the retroviral factors to relocalize SERINC5, which
is removed from the plasmamembrane, and prevented from accessing
nascent virions.
The anti-HIV-1 activity of SERINC5
Which step of the HIV-1 life cycle is blocked by SERINC5 was inves-
tigated next. HIV-1 produced in the presence of SERINC5–HA failed
to accumulate products of reverse transcription in target cells, con-
firming previous reports that in the absence of Nef the infection
process is halted at an early stage of the HIV-1 life cycle (Fig. 5a).
Whether Nef affects fusion between the virion particle and the target
cell membrane has remained questionable25,32–37. We therefore
developed a novel protein transduction assay in which the bacterio-
phage Cre recombinase fused to a nuclear localization signal flanked
by HIV-1 protease cleavage sites (Fig. 5b) is packaged as part of the
Gag polyprotein into HIV-1 particles (Extended Data Fig. 3a). Cre,
delivered into the cell after fusion, activates expression of a reporter
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gene (nlsRFP) following loxP recombination. Confirming the
ability to detect cytoplasmic delivery of Cre independently of
productive infection, Cre-mediated reporter activation was not
blocked by the reverse transcriptase inhibitor azidothymidine
(AZT) but was blocked by the fusion inhibitor T20 (Extended
Data Fig. 3b).
Increasing expression of SERINC5 in producer cells did not
affect the amount of Cre associated with virions (Extended Data
Fig. 3c), but resulted in a gradually increased inhibition of Cre-
mediated activation of the reporter gene in target cells by Nef-
defective HIV-1 (Fig. 5c), with a 25-fold inhibition observed at
the highest SERINC5 expression level, which in turn inhibited
infectivity by 250-fold (Fig. 5c). This observation was reproducible
also using a fusion assay based on the viral incorporation and
cytoplasmic delivery of a BLAM-VpR chimaeric gene38 (Extended
Data Fig. 3d). By contrast, Cre-delivery from Nef-defective HIV-1
pseudotyped with VSV-G (Fig. 5d) or with EBOV GP (Extended
Data Fig. 3e) was not inhibited by SERINC5, consistent with the
intrinsic resistance of these pseudotypes to the inhibition by the
host factor (Fig. 3b).
When the host factor was expressed at a level which introduced a
20-fold effect on infectivity, SERINC5 resulted in a 2–3-fold
inhibition of Cre delivery, fully counteracted by Nef (Extended
Data Fig. 3f). Similarly, Nef-defective HIV-1 derived from wild-
type JTAg cells delivered Cre to target cells with a 2–3-fold lower
efficiency than Nef-positive virions in the presence of endogen-
ously expressed SERINC5, in spite of a 20-fold lower infectivity
(Fig. 5e).
Altogether, these results suggest that SERINC5 perturbs the
ability of the viral particle to translocate its content to the
cytoplasm.
Discussion
Here we demonstrate that SERINC5, and to a lesser extent SERINC3,
are responsible for the long-sought anti-HIV-1 activity that is over-
come by Nef. These cellular proteins join a growing list of host factors
that inhibit retrovirus infection and are referred to as restriction fac-
tors. However, SERINC5 and SERINC3 have features that distinguish
them from other known retroviral restriction factors. For example,
SERINC5 expression in primary CD41 T cells or dendritic cells is not
upregulated by type I interferon or by an interferon-inducing agent
such as lipopolysaccharide (LPS; ExtendedData Fig. 4). SERINC5 and
SERINC3 therefore appear to be examples of constitutively expressed
intrinsic restriction factors.
Human SERINC5 shares 28% identity at the amino acid level with
the Saccharomyces cerevisiae orthologue, TMS1 (ref. 18). Such a
degree of conservation suggests a yet unidentified core biological
function in cells and represents another peculiar feature compared
with other antiretroviral restriction factors (for example, TRIM5
could be traced back only to teleosts39), which diversified under strong
positive selection40. Remarkably, Nef from HIV-1 and SIV, as well as
glycoGag from MLV, are all capable of counteracting human
SERINC5, denoting an unusual low species-specificity between the
host factor and the viral antagonist.
We provided evidence that SERINC5 perturbs the ability of small
intravirion proteins, such as Cre and BLAM-VpR (less than 40 kDa),
to access the target cell. However, inhibition of infectivity by
SERINC5 is tenfold higher, suggesting that infection is blocked des-
pite detectable fusion. The effect on infectivity, which requires the
delivery of the 60–120-nm viral core41, is therefore unlikely to be
explained only by an effect of SERINC5 on the initial membrane
fusion event. The host protein could therefore affect a step after the
fusion pore generation, required for the translocation of the viral core
(Fig. 5f). After the initial membrane fusion triggered by fusogenic
glycoproteins, the formation of a fusion pore is followed by its expan-
sion, the highest energy requiring step in the fusion process42. This
event is known to be affected by the lipid membrane composition43,44
and the presence of proteins altering the rigidity and the curvature of
the lipid bilayer45. How SERINC5 would affect this step of HIV-1
infection remains to be established. By contrast, VSV-G or EBOV
GP may override such inhibition by intrinsically promoting more
efficient expansion of the fusion pore. Interestingly, some HIV-1
Env glycoproteins from clinical isolates appear also to modulate the
susceptibility of the virus to SERINC5 inhibition (Fig. 3c), suggesting
the possibility that HIV-1 uses Env in addition to Nef to overcome
such a powerful block.
In conclusion, the ability to target evolutionary distant retroviruses
(HIV andMLV) and the convergent evolution of antagonistic retroviral
factors (Nef and glycoGag) indicate that SERINC5 has a fundamental
role in the interaction of the host with retroviral pathogens.
Interestingly, ectopic expression of SERINC5 potently inhibits HIV-1,
even in thepresence ofNef (Fig. 2g), suggesting that this cellular antiviral
factor might be exploited as an anti-HIV-1 therapeutic gene.
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METHODS
Plasmids. Env-defective and nef-defective HIV-1NL4-3 have been described prev-
iously22. Env-defective and glycoGag-defective MLV were engineered to express
GFP in place of Env. Unless otherwise indicated, single round HIV-1 Env-defective
HIV-1 (NL4-3) was complemented with Env derived from HIV-1HXB2 expressed
with the vector PBJ5 (ref. 22). Constructs for expression of other viral factors
include: plasmids encoding Env from primary HIV-1 isolates (obtained from
NIH AIDS Reagent Program); plasmids encoding wild-type and mutated HA-
tagged Nef from HIV-1LAI 22 and Nef from primary HIV-1 isolates belonging to
subtypes C, D, F; plasmids for expression of HA-tagged Nef from SIVmac and
SIVagm22; plasmids encoding untagged or HA-tagged MLV glycoGag truncated
at residue 189 (ref. 16), pCAGGS expressing codon optimized Zaire Ebola virus
glycoprotein (GenBank accession numberKJ660346.2); pMDG46 encodingVSV-G.
DNA encoding SERINC5 with or without the HA-tag were amplified from
cDNA derived from JTAg cells. DNA sequence was confirmed to match the ref-
erence sequence with accession number NM_001174072.2. DNA encoding
SERINC3 (reference sequence NM_006811) was custom synthesized (GeneWiz).
For expression in mammalian cells, DNAs were cloned into expression vectors
PCDNA3.1 (Life Technologies), PBJ5, PBJ6 (derived from PBJ5 by removing the
SV40 origin of replication from the SV40-HTLV-1 hybrid promoter region), and
pEGFPN1 (Clontech).
Increasing amount of SERINC5–HA expression in HEK293T cells was
obtained by transfecting cells with PBJ6-, PBJ5-, and PCDNA3.1-based vector
in increasing order (PBJ6,PBJ5,PCDNA3.1).
mRFP–Rab7 was a gift from A. Helenius (Addgene plasmid 14436).
TagRFP657 was fused at the C terminus of Nef to generate pNef-Tag-RFP.
Cell lines. Cell lines used (also described in Extended Data Table 1 together with
the source) were all tested for possible contamination with mycoplasma and
tested negative. Cell line TE671 (Fig. 1a) is listed in the ICLAC database of
commonly misidentified cell lines. However, for our purposes the nature of the
cell line does not influence the outcome of the research which was only meant at
investigating a correlation between the Nef requirement with gene expression. In
addition to cell lines listed in Extended Data Table 1, TZM-bl indicator cells were
obtained from the NIH AIDS Research and Reference Reagent program.
CRISPR-Cas9 knockout. Stable cell lines knocked out for SERINC5 were gen-
erated by transductionwith LentiCRISPR (a gift fromF. Zhang, Addgene plasmid
49535) after puromycin selection and, where indicated, clonal expansion. PX330
CRISPR-Cas9 (a gift from F. Zhang, Addgene plasmid 42230) was used for
generating knockout by transient transfection, targeting simultaneously two dif-
ferent exons of the same gene. The following target sequences were used: 59-GC
TGAGGGACTGCCGAATCC-39 (SERINC5-1, exon 2), 59-GACGGCTCCCAC
ATAGCGCC-39 (SERINC5-2, exon 6), 59-GGCGTACCACAGCTTGTTAC-39
(SERINC5-3, exon 8), 59-GCATCGGCATAGCAAACACG-39 and 59-CTATGC
CGATGCTGTCCTAG-39 (SERINC1), 59-CCGCATGTGCTTCGCCACGG-39
and 59-ATCCTGGTGGGCCTCACCGT-39 (SERINC2), 59-ATAAATGAGGC
GAGTCACCG-39 and 59-CTCCGAGCGGCAGTACACAA-39 (SERINC3),
59-TGATGACAGAAGCTTGTAGG-39 and 59-GGTTCCATTTTACTCAGGC
C-39 (SERINC4), 59-GTGAACCGCATCGAGCTGAA-39 (GFP).
To verify the occurrence of indels and the disruption of the SERINC5 open-
reading frame (ORF) in clonal populations of JTAg cells stably transduced with
the LentiCRISPR vector targeting SERINC5 exon 2 (using SERINC5-1 gRNA),
genomicDNAwas extracted from cells, a 228-nucleotide fragment encompassing
exon 2 was amplified by PCR using primers 59-TCGTCGGCAGCGTCAGATG
TGTATAAGAGACAG-TAAGCAGATGCCTTCTGTTCCTT-39 and 59-GTCT
CGTGGGCTCGGAGATGTGTATAAGAGACAG-AATAGGACGAGCTGAAC
ACGG-39 (in which italic denotes the locus-specific sequence, and bold denotes
the overhang adapters). A subsequent limited-cycle amplification step was per-
formed to add multiplexing indices and Illumina sequencing adapters.
Normalized and pooled libraries were, then, sequenced on the Illumina MiSeq
system using v2 reagents (23250-nucleotide paired-end reads).
Viruses and infectivity assay. Cell lines in Fig. 1a were infected with NL4-3 and
NL4-3Nef2 produced by transfection of HEK293T cells and transiently pseudo-
typed with VSV-G. Virus supernatant was collected 48 h after infection and
inoculated onto TZM-bl cells in the presence of the protease inhibitor
Saquinavir (10mM) to limit infection to a single round of replication.
For all other experiments, virions limited to a single round of replication were
used and were produced by transfection. JTAg and 174XCEM cells were trans-
fected using electroporation, HT1080 usingMirus TransIT-2020, HEK293T cells
by the calcium phosphate co-precipitation method. PBMC were transfected by
nucleofection 48 h after stimulation with phytohaemagglutinin (PHA) and inter-
leukin-2 (IL-2). As indicated, virus constructs were co-transfected together with
other plasmids expressing Env glycoproteins, Nef, glycoGag, SERINC5, or
PX330-based CRISPR-Cas9 vectors. Virus-containing culture supernatants were
collected 48 h after transfection, clarified by centrifugation at 300g for 5 min and
passed through filters with 0.45-mm pores. Virus prepared in quadruplicate were
then quantified using the SG-PERT reverse transcription assay47, diluted three- or
fivefold in a series of six steps and used to infect TZM-GFP reporter cells seeded
one day before infection in 96-well plates. TZM-GFP is a modified version of
TZM-bl containing an integrated nlsGFP reporter gene under the transcriptional
control of the HIV-1 long terminal repeat. Infection of reporter cells was scored
using the High Content Imaging System Operetta (Perkin Elmer) after counter-
staining nuclei with Hoechst 33342 for each virus dilution. Those values falling
into a linear dilution range (normally below 20% of infected cells) were used to
calculate infectivity. Infectivity was calculated by dividing the number of infected
cells in a well for the amount of reverse transcriptase activity associated to the
virus inoculum, measured in mU47.
Heterokaryons. Heterokaryons were produced following a strategy previously
reported48. Production of single round virions infectious only upon heterokaryon
formation was obtained by transfecting one fusion partner with env-defective/
nef-defectiveHIV-1NL4-3 and the other with PBJ5-HXB2-Env, PBJ5-NefLAI or the
empty control vector PBJ5. To promote efficient fusion mediated by HIV-1 Env,
plasmids encoding for CD4 and CXCR4 were co-transfected together with
the env-defective provirus construct. Then 24 h after transfection, cells were
co-cultured and progeny viruses collected 24 h later.
Preparation of RNA-seq libraries and sequencing. Five micrograms of total
RNA extracted from seven highly Nef-dependent cell lines (JTAg, Jurkat E6.1,
bl41, Ramos, CEM A301, CEM SS and HSB2) and eight low Nef-dependent cell
lines (MT4, HT1080, RAJI, DAUDI, C8166, IMR90, CEMX174 and WI38) was
subjected to rRNA depletion using Ribo-Zero Magnetic Gold Kit (Epicentre).
RNA-seq libraries were prepared from the rRNA depleted RNAs extracted from
the 15 cell lines (Fig. 1a) using a modified protocol of the Illumina TruSeq RNA
Sample Prep Kit. Libraries were sequenced on the Illumina HiSeq 2000 using
paired-end sequencing 23 100 bp. Raw reads were mapped against the human
(hg19) genome reference using tophat2 (ref. 49). RPM50 values were estimated for
each transcript in each samplewith a custompipeline. Geneswere ranked accord-
ing to Pearson correlation between their relative expression (RPM) in cell line and
the corresponding Nef1/Nef2 infectivity ratio (Fig. 1a). The computations were
performed at the Vital-IT Center (http://www.vital-it.ch) for high-performance
computing of the SIB Swiss Institute of Bioinformatics in Geneva.
Microscopy. JTAg cells were electroporated with constructs expressing Nef-
TagRFP657 or the control TagRFP657, Nef–HA, HA–glycoMa, SERINC5–GFP
and Rab7–RFP as indicated. Then 48 h after transfection, cells were overlaid on
poly-L-lysine coated glass slides, fixed with 4% paraformaldehyde and permea-
bilzed with 0.1% Triton X-100. The HA tag was detected by staining with mouse
anti-HA (HA.11, Covance) and the secondary antibody Alexa 633 (Life
Technologies). Images were acquired using a Leica TCS SP5 confocalmicroscope.
Western blotting. Cell lysates and virion pellets were analysed by SDS–PAGE
and western blotting. In brief, viral particles were collected 48 h after transfection,
centrifuged at 300g to remove cell debris and filtered. The clarified supernatants
were overlaid on 25% sucrose cushion and concentrated at 100,000g. The pellets
were resuspended directly in Laemmli buffer (supplemented with 50mMTCEP),
normalized by reverse transcriptase assay and resolved by SDS–PAGE. After
observing that SERINC5 and SERINC3 form aggregates that are lost while
clarifying the cell lysate or fail to enter the separating gel, cells were lysed directly
in Laemmli buffer containing TCEP (Sigma, final concentration 50mM, pH 7.0)
and avoiding boiling. Sampleswere loaded on gel after a 5-pulse sonication.Having
failed to find a commercially available antibody capable of detecting the endogen-
ous protein, probing was performed using mouse anti-HA (HA.11, Clone 16B12,
Covance), mouse or rabbit anti-b-actin (Li-COR), anti-HIV-1 p55/p24 (National
Biological Standards Board), anti-gp41 Chessie-8 (obtained from the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH from G. Lewis), mouse
anti-Cre (Mab3120, Chemicon) and secondary antibodies IRDye 680 and IRDye
800 (Li-COR). Blots were imaged using an Odyssey Imager system (Li-COR).
nlsCre delivery assay.Apackaging vector based on p8.9 lentiviral gag-pol expres-
sing plasmid46 (8.9-Cre) was generated to carry an insertion of nlsCre between
MA and CA flanked by native HIV-protease cleavage sites for processing and
release of proteins from Gag.
A Cre-responsive nuclear RFP-expressing lentiviral vector (p-lenti LoxP-
Blasti-mRFP) was created. It consists of a nls-mRFP sequence lacking the trans-
lation initiation codon and preceded by a sequence encoding the blasticidin
antibiotic resistance (Bla) between two loxP sites. The nlsRFP is translationally
inactive unless Cre-mediated recombination of loxP and excision of Bla occurs,
providing an authentic translation initiation for mRFP. A TZM-bl-GFP deriv-
ative cell line (TZM-GFP) stably transduced with p-lenti LoxP-Blasti mRFP was
generated (TZM-GFP-LoxP-RFP) to detect delivery of nlsCre, and Tat-driven
expression of nlsGFP.
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To package nlsCre in retrovirus particles, HIV-1 was produced by mixing 8.9-
Cre together with the env-defective (and nef-defective where applicable) NL4-3
provirus at a ratio of 1:2. Virus was produced by cotransfecting HEK293T cells
with the viral constructs together with PBJ5-HXB2-env or vectors for expression
of VSV-G and Ebola glycoprotein, and plasmids encoding SERINC5 or the empty
vector. To achieve increasing level of expression, SERINC5 was expressed from
vector PBJ6, PBJ5 and PCDNA3.1 (in increasing order). Progeny virus was
inoculated onto TZM-GFP-LoxP-RFP and red and green fluorescence quantified
48 h later using the High Content Imaging System Operetta (Perkin Elmer) after
counterstaining nuclei with Hoechst 33342, following the method described for
infectivity.
BLAM-VpR assay. Virus was produced by transfection of HEK293T with the
calcium phosphate method in 10 cm tissue culture plates with 10 mg of NL4-3
Envfs/Neffs (bearing a frameshift) together with 2mg HIV-1 Env expressor, 5mg
of BLAM-VpR vector38 and 5 mg of SERINC5 expression vectors or the empty
vector control.
Target cells (TZM-bl) were seeded in clear bottom 96-well plates (Optiplates,
Perkin Elmer) at a density of 25,000 cells per well in phenol-Red-freemediumone
day before assay. Virus samples were normalized for reverse transcriptase activity
content and added to wells (200ml) serially diluted as described for infectivity.
Cells were spin-infected for 2 h at 4 uC at 1,550g, virus was removed, cells washed
twice with complete medium and incubated for 90 min at 37 uC. Medium was
then replaced with GeneBlazer substrate loading solution containing 2mM
CCF2AM (GeneBLAzer In vivo Detection Kit, Life Technologies) and 2.5mM
Probenecid (Sigma). Cells were incubated overnight at 11 uC, fixed with 2%
paraformaldehyde and plates analysed using the Operetta imaging system for
blue and green fluorescence to reveal the number of blue positive cells.
Transduction units were derived from the number of blue positive cells divided
per reverse transcriptase activity associated to the virus inocula as described for
infectivity.
Quantification of HIV-1 reverse transcription products. NL4-3 normalized
based on reverse transcriptase activity was incubated with target cells (NP2-
CD4-CXCR4). Cell-free virions were normalized by reverse transcriptase activity
and incubated with target cells in 6-well plates for 12 h. For each virus, infections
were also performed in the presence of 40mMAZT, to control for contamination
of plasmidDNA in the PCR reaction. Cells were collected and washed extensively
with PBS. Total DNA was extracted (Qiagen, Qiamp DNA mini kit), quantified,
and subjected to real-time PCR with a Biorad CFX96 cycler. cDNA was detected
with SYBR-Green I based reactions using 100 ng template DNA and 320 nM of
each primer pair (59-ACAAGCTAGTACCAGTTGAGCCAGATAAG-39 and
59-GCCGTGCGCGCTTCAGCAAGC-39) in 20mM Tris-Cl, pH 8.3, 5mM
(NH4)2SO4, 20mM KCl, 5mM MgCl2, 0.1mgml
21 BSA, 1/20,000 SYBR Green
I (Sigma), and 200mM dNTPs. The PCR was programmed for 40 cycles of
denaturation at 95 uC for 5 s, annealing 55 uC for 5 s, extension at 72 uC for 20 s
and acquisition at 80 uC for 5 s. Relative quantification of retroviral cDNA
sequences was obtained with respect to standard curves prepared from serial
dilutions of DNA derived from the cell culture with the highest infection, diluted
in DNA extracted from non-infected cells.
PBMC. Buffy coats obtained from anonymous blood donors were provided by
the Department of Immunotransfusion, Padova University Hospital, for experi-
ments involving virus production, or purchased from the New York Blood
Center, for interferon induction studies. PBMC were isolated using Ficoll-
Paque Plus (GE Healthcare).
Isolation, stimulation and treatment of dendritic cells.CD141monocytes were
enriched from PBMC by positive selection using CD14 MicroBeads following the
manufacturer’s protocol (Miltenyi Biotec). CD141-enriched cell populations were
counted, centrifuged at 200g for 10min, and resuspended at 23 106 cellsml21 in
RPMI-1640 supplemented with 5% human AB1 serum, 1 3 MEM non-essential
amino acids (NEAA), 20mML-glutamine, 25mMHEPES, 1mM sodiumpyruvate
and 50 mM b-mercaptoethanol. To induce differentiation of monocytes into
dendritic cells, cells were cultured for 5 days in GM-CSF (50 ngml21) and IL-4
(25 ngml21), both cytokines from R&D Systems. Dendritic cells were treated with
LPS (100ngml21, LPS-EKUltrapure, Invivogen) or IFN-b (37ngml21, PBLAssay
Science). Cells were collected at various time points (t5 0 h, 2 h, 6 h, 24 h) after the
LPS and IFN-b treatments for RNA extraction and subsequent RT–PCR analysis.
Isolation, stimulation and treatment of CD41 T cells. CD41 T cells were
isolated from CD14-depleted PBMCs by positive selection using CD4 magnetic
microbeads (Miltenyi Biotec) and plated at 23 106 cellsml21 in RPMI-1640,
supplemented with 10% FBS, 25mM HEPES, 1mM sodium pyruvate, 13
MEM NEAA, and 13 GlutaMAX (Life Technologies). In one experiment,
CD41 T cells were treated directly with LPS (100 ngml21) or IFN-b (37 ngml21,
PBL Assay Science). Separately, CD41 T cells from the same donors were stimu-
lated with 4mgml21 of PHA-M for 48h, 20 IUml21 IL-2was added, and cells were
stimulated with LPS or IFN-b. Cells were collected at various time points (t5 0 h,
2 h, 6 h, 24h) after the LPS and IFN-b treatments for RNA extraction and sub-
sequent RT–PCR analysis. Jurkat T cells were cultured and stimulated similarly.
RNA isolation and qRT–PCR. RNA was isolated using RNeasy Plus Mini Kit
(Qiagen 74134) with additional on column DNase treatment (Qiagen 79254)
and reverse transcribed with SuperScript VILO Master Mix (Invitrogen
11755050). Gene expression was assayed on a Biorad CFX96 Real-Time PCR
detection system.
For quantification of SERINC5 transcripts in cell lines and PBMC (Extended
Data Fig. 2c), the SYBR-Green-based real-time PCR method was used with the
following primers 59-TAAGCAGATGCCTTCTGTTCCTT-39 and 59-AATAG
GACGAGCTGAACACGG-39 (for SERINC5) and 59-GACAGGATGCAGAAG
GAGATTACTG-39 and 59-CTCAGGAGGAGCAATGATCTTGAT-39 (for
b-actin used as normalization control).
For Extended Data Fig. 4, gene expression was measured using TaqMan Gene
Expression Master Mix (Life Technologies 4369016) and the following TaqMan
probes and primers sets: SERINC5 (Hs00968169_m1, Life Technologies
4351372) and SERINC3 (Hs01566572_m1), CXCL10 (Hs00171042_m1) and,
as a normalization control,OAZ1 (Hs00427923_m1, Life Technologies 4331182).
Statistics. Statistical tests were performed using GraphPad Prism. Given the
nature of the experiments and the type of samples, significance of differences
was assessed with unpaired two-tailed Student’s t-test. Variance was estimated by
calculating the standard deviation in each group, as represented by error bars.
Variances between groups of samples were compared using the F-test function
integrated in GraphPad. No statistical methods were used to predetermine
sample size. Unless otherwise specified in figure legends, all experiments were
performed independently at least three times and ‘n’ indicates technical repli-
cates, with a representative experiment being shown. Experiments were not ran-
domized, and the investigators were not blinded to allocation during experiments
and outcome assessment.
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Extended Data Figure 1 | SERINC5 is an inhibitor of HIV-1 infectivity.
a, Mapping of the INDELS in the genomic locus spanning SERINC5 exon 2
in JTAg cell clonal populations from Fig. 2a. b, Infectivity of HIV-1 from JTAg
cells stably transduced with lentiCRISPR targeting GFP or SERINC5 in
three different exons (n5 4, experiment replicated twice). c, Relative
expression of SERINC5 in primary cells and in cell lines measured by qPCR
normalized by expression of ACTB (n5 3). d, Infectivity of HIV-1 from
the indicated cell lines expressing SERINC5 (n5 4, experiments were
replicated twice). Mean 6 s.d., unpaired two-tailed t-test, ***P, 0.001
e, Expression levels of the five SERINC genes in JTAg cells obtained
from RNA-seq.
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Extended Data Figure 2 | Nef and glycoGag expression result in
relocalization of SERINC5 to an endosomal compartment and prevent
its incorporation into virions. a, Single round Nef-defective NL4-3 produced
by cotransfection of HEK293T cells with plasmids expressing Nef proteins
or the empty vector control, and PBJ6-SERINC5–HA: immunoblotting of
virions and cell lysates from producer cells. b, Immunofluorescence staining
of JTAg cells transfected to express SERINC5–GFP, Nef–HA from HIV-1
isolate 97ZA012 (clade C), from SIVmac239, HA–glycoGag or an empty
vector control. Scale bar, 10 mm.
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Extended Data Figure 3 | SERINC5 inhibits cytoplasmic delivery of virion
content. a, Immunodetection of Cre-recombinase (38 kDa) and p24 in HIV-1
particles. b, Effect of 1 mM AZT or 100 nM T20 on Cre-delivery and virus
infectivity (TU, transducing units). c, Immunoblotting of HIV-1 virus particles
produced from HEK293T expressing increasing levels of SERINC5–HA.
d, Effect of SERINC5 on virus fusionmeasured with BLAM assay T20 served as
a negative control. (n5 4, experiment replicated twice). e, Cre delivery by
EBOV-GP pseudotyped HIV-1 particles. f, Inhibition of Cre delivery
and counteraction by Nef on HIV-1 from HEK293T expressing SERINC5.
Mean 6 s.d., n5 4, unpaired two-tailed t-test, *P, 0.05, **P, 0.01,
***P, 0.001. Scale bar, 100mm.
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ExtendedData Figure 4 | SERINC3 andSERINC5 expression is not induced
by interferon nor LPS treatments. a–d, Relative gene expression levels of
SERINC3, SERINC5 andCXCL10 in response to treatment with IFN-b and LPS
in Jurkat (a), monocyte-derived dendritic cells from two donors (MDDC, b),
CD41 primary T cells unstimulated (c) or stimulated with PHA (d) from two
donors. Expression of the housekeeping gene OAZ1 was used as a
normalization control. Mean 6 s.d., n5 3.
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Extended Data Table 1 | Description of the cells lines used in Fig. 1a
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